

Anastrozole alone or in combination with tamoxifen versus
tamoxifen alone for the adjuvant treatment of postmenopausal women with early-stage breast cancer

Cancer

2017, 98, 1802-1810

DOI: [10.1002/cncr.11745](https://doi.org/10.1002/cncr.11745)

Citation Report

#	ARTICLE	IF	CITATIONS
1	2000 Highlights From: 23rd Annual San Antonio Breast Cancer Symposium; San Antonio, Texas December 6-9, 2000. <i>Clinical Breast Cancer</i> , 2001, 1, 264-269.	1.1	0
2	Adjuvant aromatase inhibitors. <i>Cancer</i> , 2003, 98, 1779-1781.	2.0	7
3	Current Status of Aromatase Inhibitors in the Management of Breast Cancer and Critique of the NCIC MA-17 Trial. <i>Cancer Control</i> , 2004, 11, 217-221.	0.7	27
5	Treatment options for early breast cancer in elderly women. <i>Expert Review of Anticancer Therapy</i> , 2004, 4, 197-211.	1.1	12
6	Raloxifene and its role in breast cancer prevention. <i>Expert Review of Anticancer Therapy</i> , 2004, 4, 523-532.	1.1	11
7	Toward New Horizons: The Future of Bisphosphonate Therapy. <i>Oncologist</i> , 2004, 9, 38-47.	1.9	46
8	Shifting paradigms in hormonal therapy for breast cancer. <i>Cancer Biology and Therapy</i> , 2004, 3, 797-805.	1.5	2
9	Changes in endocrine therapy: Anastrozole and advanced breast cancer in postmenopausal women. <i>American Journal of Hospice and Palliative Medicine</i> , 2004, 21, 457-465.	0.8	0
10	Fertility Options in Young Breast Cancer Survivors: A Review of the Literature. <i>Oncology Nursing Forum</i> , 2004, 31, E46-E53.	0.5	37
11	Quality of Life of Postmenopausal Women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. <i>Journal of Clinical Oncology</i> , 2004, 22, 4261-4271.	0.8	283
12	Exemestane Following Tamoxifen in Postmenopausal Women With Primary Breast Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 3833-3834.	0.8	6
13	Controversies in the adjuvant treatment of breast cancer: new adjuvant endocrine treatment strategies. <i>Annals of Oncology</i> , 2004, 15, iv23-iv29.	0.6	4
15	Can exemestane improve adjuvant treatment for postmenopausal women with primary breast cancer?. <i>Nature Clinical Practice Oncology</i> , 2004, 1, 24-25.	4.3	2
17	Advances in Endocrine Therapy for Breast Cancer: Considering Efficacy, Safety, and Quality of Life. <i>Clinical Journal of Oncology Nursing</i> , 2004, 8, 629-637.	0.3	21
18	Deja Vu for Breast Cancer Two?. <i>Journal of the National Cancer Institute</i> , 2004, 96, 497-499.	3.0	3
19	Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention. <i>Annals of Oncology</i> , 2004, 15, 1738-1747.	0.6	18
20	Use of Aromatase Inhibitors in the Adjuvant Setting: The "Switching" Trials. <i>Clinical Breast Cancer</i> , 2004, 5, 31-34.	1.1	1
21	Future options with trastuzumab for primary systemic and adjuvant therapy. <i>Seminars in Oncology</i> , 2004, 31, 51-57.	0.8	45

#	ARTICLE	IF	CITATIONS
22	Aromatase inhibitors in early breast cancer therapy. <i>Seminars in Oncology</i> , 2004, 31, 9-14.	0.8	53
23	Aromatase inhibitors in the management of early breast cancer: Optimizing the clinical benefit. <i>Seminars in Oncology</i> , 2004, 31, 31-34.	0.8	11
24	Chemoprevention of Cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2004, 54, 150-180.	157.7	275
25	Neoadjuvant Endocrine Therapy in Primary Breast Cancer. <i>Clinical Breast Cancer</i> , 2004, 5, 341-347.	1.1	21
26	The ATAC (Arimidex®, Tamoxifen, Alone or in Combination) Trial: An Update. <i>Clinical Breast Cancer</i> , 2004, 5, S6-S12.	1.1	17
27	Switching Trial of Adjuvant Tamoxifen with an Aromatase Inhibitor in Postmenopausal Patients with Breast Cancer. <i>Clinical Breast Cancer</i> , 2004, 5, S13-S17.	1.1	10
28	Adjuvant Aromatase Inhibitors Following Tamoxifen for Early-Stage Breast Cancer in Postmenopausal Women: What Do We Really Know?. <i>Clinical Breast Cancer</i> , 2004, 5, S18-S23.	1.1	2
29	Implications of First-Line Adjuvant Treatment with Aromatase Inhibitors in Recurrent Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2004, 5, S24-S30.	1.1	0
30	Aromatase inhibitors“extending the benefits of adjuvant therapy beyond tamoxifen. <i>Breast</i> , 2004, 13, 3-9.	0.9	12
31	Are all aromatase inhibitors the same? A review of the current evidence. <i>Breast</i> , 2004, 13, 10-18.	0.9	29
32	Long-term implications of bone loss in breast cancer. <i>Breast</i> , 2004, 13, 29-37.	0.9	27
33	Translational research and the changing face of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2004, 87, 1-2.	1.1	21
34	Biomarker investigations from the ATAC trial: the role of TA01. <i>Breast Cancer Research and Treatment</i> , 2004, 87, 11-18.	1.1	13
35	The scientific value of preoperative studies and how they can be used. <i>Breast Cancer Research and Treatment</i> , 2004, 87, 19-26.	1.1	28
36	Designing the future shape of breast cancer diagnosis, prognosis and treatment. <i>Breast Cancer Research and Treatment</i> , 2004, 87, 27-29.	1.1	4
38	The curability of breast cancer and the treatment of advanced disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004, 31, S149-S161.	3.3	123
41	Breast surgery in the “Arimidex, Tamoxifen Alone or in Combination” (ATAC) trial. <i>Cancer</i> , 2004, 101, 735-740.	2.0	33
42	Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. <i>Cancer</i> , 2004, 101, 1311-1322.	2.0	70

#	ARTICLE	IF	CITATIONS
43	The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma. <i>Cancer</i> , 2004, 101, 1482-1489.	2.0	33
44	A review of adjuvant hormonal therapy in breast cancer. <i>Endocrine-Related Cancer</i> , 2004, 11, 391-406.	1.6	52
45	Advances in Screening, Diagnosis, and Treatment of Breast Cancer. <i>Mayo Clinic Proceedings</i> , 2004, 79, 810-816.	1.4	24
46	E9. Side-effects of tamoxifen and solutions with aromatase inhibitors. <i>European Journal of Cancer, Supplement</i> , 2004, 2, 33-34.	2.2	2
48	Endocrine treatment and prevention of breast and gynaecological cancers. <i>European Journal of Cancer, Supplement</i> , 2004, 2, 1-14.	2.2	0
49	Should Tamoxifen Be Used in Breast Cancer Prevention?. <i>Drug Safety</i> , 2004, 27, 979-989.	1.4	11
50	Letrozole sensitizes breast cancer cells to ionizing radiation. <i>Breast Cancer Research</i> , 2004, 7, R156-63.	2.2	65
51	Endocrinology and hormone therapy in breast cancer: Aromatase inhibitors versus antioestrogens. <i>Breast Cancer Research</i> , 2004, 6, 269-74.	2.2	49
54	Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard?. <i>Cancer Treatment Reviews</i> , 2004, 30, 325-332.	3.4	125
55	Switching to exemestane after 2-3 years of adjuvant tamoxifen prolongs disease-free survival, but not overall survival, in postmenopausal women surviving primary breast cancer, compared with continuous tamoxifen. <i>Cancer Treatment Reviews</i> , 2004, 30, 583-588.	3.4	0
56	Endocrine approaches for the treatment of early and advanced breast cancer in postmenopausal women. <i>International Journal of Biochemistry and Cell Biology</i> , 2004, 36, 2112-2119.	1.2	10
58	Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status. <i>European Journal of Cancer</i> , 2004, 40, 2742-2747.	1.3	39
59	Comparison of two-year and five-year tamoxifen use in Japanese post-menopausal women. <i>European Journal of Surgical Oncology</i> , 2004, 30, 1077-1083.	0.5	3
60	The Letrozole Breast Cancer Trial: clinical implications and remaining questions. <i>Women's Health Issues</i> , 2004, 14, 7-10.	0.9	1
61	Steroid receptors in human breast cancer. <i>Trends in Endocrinology and Metabolism</i> , 2004, 15, 316-323.	3.1	73
62	2003 Highlights From: 26th Annual San Antonio Breast Cancer Symposium; San Antonio, Texas, December 3-6, 2003. <i>Clinical Breast Cancer</i> , 2004, 4, 382-388.	1.1	0
63	E5. Molecular basis of endocrine therapy. <i>European Journal of Cancer, Supplement</i> , 2004, 2, 12-13.	2.2	0
64	Aromatase inhibitors in adjuvant therapy: promise and uncertainty. <i>Community Oncology</i> , 2004, 1, 219-224.	0.2	0

#	ARTICLE	IF	CITATIONS
65	Lymph-node-negative oestrogen-receptor-positive breast cancer. <i>Lancet</i> , The, 2004, 364, 820-821.	6.3	2
66	Role of aromatase inhibitors in the treatment of breast cancer. <i>Clinical Therapeutics</i> , 2004, 26, 1199-1214.	1.1	38
67	Time for a change in breast cancer therapy?. <i>British Journal of Hospital Medicine</i> , 2004, 65, 724-729.	0.3	0
68	The role of aromatase inhibitors as adjuvant therapy in early breast cancer. <i>Breast Cancer Online: BCO</i> , 2004, 7, .	0.1	0
69	Designing a Randomized Phase I/II Prostate Cancer Chemoprevention Trial Using 1??-Hydroxy-24-Ethyl-Cholecalciferol, an Analogue of Vitamin D3. <i>Cancer Journal (Sudbury, Mass)</i> , 2004, 10, 357-367.	1.0	8
70	Advances in Screening, Diagnosis, and Treatment of Breast Cancer. <i>Mayo Clinic Proceedings</i> , 2004, 79, 810-816.	1.4	26
71	Adjuvant Use of Anastrozole in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 1524-1526.	0.8	6
72	Adjuvant endocrine therapy for postmenopausal women with early stage breast cancer. <i>Therapy: Open Access in Clinical Medicine</i> , 2004, 1, 305-318.	0.2	0
73	Managing early breast cancer. <i>Postgraduate Medicine</i> , 2004, 116, 23-34.	0.9	2
74	Assessing breast cancer risk. <i>Postgraduate Medicine</i> , 2004, 116, 6-34.	0.9	14
75	Switching to exemestane after 2â€“3 years of adjuvant tamoxifen prolongs disease-free survival, but not overall survival, in postmenopausal women surviving primary breast cancer, compared with continuous tamoxifen. Abstracted from: Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of 3.4 exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. <i>N Engl J Med</i> 2004;350:1081â€“92.. <i>Cancer Treatment Reviews</i> , 2004, 30, 583-588.		21
76	A Randomized Trial Comparing Axillary Dissection to No Axillary Dissection in Older Patients With T1N0 Breast Cancer. <i>Annals of Surgery</i> , 2005, 242, 1-6.	2.1	181
77	Adjuvant chemotherapy in elderly patients with breast cancer: where are we?. <i>Current Opinion in Oncology</i> , 2005, 17, 566-572.	1.1	13
78	Treating elderly patients with breast cancer. <i>Breast Cancer Online: BCO</i> , 2005, 8, .	0.1	2
79	Aromatase inhibitors as adjuvant therapy: how will results of the ATAC trial at San Antonio 2004 and BIG 1-98 at St Gallen 2005 impact on aromatase inhibitors as adjuvant endocrine therapy?. <i>Breast Cancer Online: BCO</i> , 2005, 8, 1-6.	0.1	0
80	Bone Mineral Density in the Reproductive-Age Woman: <I>Effects of Medications, Pregnancy, Lactation, and Exercise. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2005, 3, 103-114.	1.3	0
81	Proliferation Marker Ki-67 in Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 7212-7220.	0.8	688
82	The evolving role of endocrine therapy for early stage breast cancer. <i>Breast Cancer</i> , 2005, 12, 62-72.	1.3	2

#	ARTICLE	IF	CITATIONS
83	Aromatase inhibitors in advanced breast cancer: there are efficacy differences. <i>British Journal of Cancer</i> , 2005, 92, 1173-1174.	2.9	1
84	Bone loss and the aromatase inhibitors. <i>British Journal of Cancer</i> , 2005, 93, S16-S22.	2.9	34
85	Risk Assessment: Controversies and Management of Moderate- to High-Risk Individuals. <i>Breast Journal</i> , 2005, 11, S11-S19.	0.4	13
86	Targeted Therapies in Breast Cancer. <i>Breast Journal</i> , 2005, 11, S30-S35.	0.4	20
87	Adjuvant endocrine therapies for postmenopausal women with early breast cancer: Standards and not. <i>Breast</i> , 2005, 14, 555-563.	0.9	6
88	Advances in the Use of Aromatase Inhibitors: Updates from San Antonio and St. Gallen. <i>Clinical Breast Cancer</i> , 2005, 6, 23-26.	1.1	8
89	Aromatase Inhibitors as Adjuvant Therapy for Postmenopausal Patients With Early Stage Breast Cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2005, 55, 145-163.	157.7	36
90	Aromatase Inhibitors for the Treatment and Prevention of Breast Cancer. <i>Clinical Breast Cancer</i> , 2005, 6, 27-37.	1.1	10
91	Defining the Roles of Aromatase Inhibitors in the Adjuvant Treatment of Early-Stage Breast Cancer. <i>Clinical Breast Cancer</i> , 2005, 6, 302-309.	1.1	11
92	Bone Health in Women with Early-Stage Breast Cancer. <i>Clinical Breast Cancer</i> , 2005, 5, S35-S40.	1.1	19
93	Evaluating Bone Mass and Bone Quality in Patients with Breast Cancer. <i>Clinical Breast Cancer</i> , 2005, 5, S41-S45.	1.1	11
94	Strategies to Prevent Chemotherapy-Induced Bone Loss in Women with Breast Cancer. <i>Clinical Breast Cancer</i> , 2005, 5, S63-S70.	1.1	9
95	Role of Fulvestrant in Sequential Hormonal Therapy for Advanced, Hormone Receptor-Positive Breast Cancer in Postmenopausal Women. <i>Clinical Breast Cancer</i> , 2005, 6, S15-S22.	1.1	5
96	Skeletal health in postmenopausal survivors of early breast cancer. <i>International Journal of Cancer</i> , 2005, 114, 1010-1015.	2.3	36
97	Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma. <i>Cancer</i> , 2005, 104, 236-239.	2.0	154
98	The natural history of breast carcinoma in patients with ≥ 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy. <i>Cancer</i> , 2005, 104, 229-235.	2.0	27
99	Clinical management of osteoporosis in women with a history of breast carcinoma. <i>Cancer</i> , 2005, 104, 443-456.	2.0	39
100	The use of aromatase inhibitors in adjuvant therapy for early breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 56, 32-38.	1.1	4

#	ARTICLE	IF	CITATIONS
101	A practical guide to the management of menopausal symptoms in breast cancer patients. <i>Supportive Care in Cancer</i> , 2005, 13, 573-578.	1.0	16
102	Long-term risk of breast cancer recurrence: the need for extended adjuvant therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2005, 131, 487-494.	1.2	28
105	Hormonal therapy for primary breast cancer: Scientific rationale and status of clinical research. <i>Current Oncology Reports</i> , 2005, 7, 31-37.	1.8	1
106	Evolving treatment approaches for early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2005, 89, S1-S7.	1.1	3
107	Letter to the editor. <i>Statistics in Medicine</i> , 2005, 24, 1609-1609.	0.8	1
108	Adjuvant use of aromatase inhibitors in postmenopausal women with breast cancer. <i>American Journal of Health-System Pharmacy</i> , 2005, 62, 266-273.	0.5	15
109	Aromatase Inhibitors in Postmenopausal Breast Cancer Patients. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2005, 3, 309-314.	2.3	20
110	Effect of anastrozole and tamoxifen on lipid metabolism in Japanese postmenopausal women with early breast cancer. <i>Acta Oncologica</i> , 2005, 44, 134-141.	0.8	22
111	Aromatase Inhibitors for Breast Cancer Prevention. <i>Journal of Clinical Oncology</i> , 2005, 23, 1636-1643.	0.8	175
112	Advances in Adjuvant Hormonal Therapy for Postmenopausal Women. <i>Journal of Clinical Oncology</i> , 2005, 23, 1751-1759.	0.8	62
113	Aromatase Inhibitors in Adjuvant Therapy of Breast Cancer: Before, Instead of, or Beyond Tamoxifen. <i>Journal of Clinical Oncology</i> , 2005, 23, 4850-4852.	0.8	21
114	Safety Considerations of Adjuvant Therapy in Early Breast Cancer in Postmenopausal Women. <i>Oncology</i> , 2005, 69, 1-9.	0.9	25
115	Biomarker Changes During Neoadjuvant Anastrozole, Tamoxifen, or the Combination: Influence of Hormonal Status and HER-2 in Breast Cancer—A Study from the IMPACT Trialists. <i>Journal of Clinical Oncology</i> , 2005, 23, 2477-2492.	0.8	263
116	Effect of Exemestane on Tamoxifen Pharmacokinetics in Postmenopausal Women Treated for Breast Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 8722-8727.	3.2	27
117	How Rapidly Do Oncologists Respond to Clinical Trial Data?. <i>Oncologist</i> , 2005, 10, 15-21.	1.9	15
118	Tailoring a tailored treatment: the importance of fine-tuning on the patient. <i>Annals of Oncology</i> , 2005, 16, 683-685.	0.6	0
119	Retrospective Analysis of Time to Recurrence in the ATAC Trial According to Hormone Receptor Status: An Hypothesis-Generating Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 7512-7517.	0.8	248
120	The Role of Growth Factor Receptor Pathways in Human Breast Cancer Cells Adapted to Long-term Estrogen Deprivation. <i>Cancer Research</i> , 2005, 65, 3903-3910.	0.4	104

#	ARTICLE	IF	CITATIONS
121	Optimizing Adjuvant Endocrine Therapy in Postmenopausal Women With Early-Stage Breast Cancer: A Decision Analysis. <i>Journal of Clinical Oncology</i> , 2005, 23, 5178-5187.	0.8	93
122	Sex hormones and related compounds, including hormonal contraceptives. <i>Side Effects of Drugs Annual</i> , 2005, , 480-504.	0.6	0
123	Optimum Use of Aromatase Inhibitors in the Adjuvant Treatment of Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 8544-8546.	0.8	6
124	HER2 or Not HER2: That Is the Question. <i>Journal of Clinical Oncology</i> , 2005, 23, 3656-3659.	0.8	24
125	Case 24-2005: A Woman with Estrogen-Receptorâ€“Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2005, 353, 2304-2305.	13.9	0
126	Case 24-2005. <i>New England Journal of Medicine</i> , 2005, 353, 617-622.	13.9	2
127	Extended adjuvant endocrine therapy of early breast cancer. <i>Current Medical Research and Opinion</i> , 2005, 21, 1985-1995.	0.9	5
128	Fulvestrant in the treatment of postmenopausal women with advanced breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 445-453.	1.1	6
129	Breast cancer and sex steroids: Critical review of epidemiological, experimental and clinical investigations on etiopathogenesis, chemoprevention and endocrine treatment of breast cancer. <i>Gynecological Endocrinology</i> , 2005, 20, 343-360.	0.7	38
130	A review of exemestane in the management of breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 2353-2363.	0.9	2
131	Reply: aromatase inhibition in advanced breast cancer: no conclusive evidence of efficacy differences. <i>British Journal of Cancer</i> , 2005, 92, 1175-1176.	2.9	1
132	Potential use of COX-2â€“aromatase inhibitor combinations in breast cancer. <i>British Journal of Cancer</i> , 2005, 93, S10-S15.	2.9	30
133	Adjuvant Endocrine Therapy for Premenopausal Women With Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 1736-1750.	0.8	79
134	Regulation of Aromatase Expression in Estrogen-Responsive Breast and Uterine Disease: From Bench to Treatment. <i>Pharmacological Reviews</i> , 2005, 57, 359-383.	7.1	455
135	Radiation Therapy and Tamoxifen: Concurrent or Sequential? It's No Longer the Question!. <i>Journal of Clinical Oncology</i> , 2005, 23, 4239-4241.	0.8	16
136	Neoadjuvant Treatment of Postmenopausal Breast Cancer With Anastrozole, Tamoxifen, or Both in Combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) Multicenter Double-Blind Randomized Trial. <i>Journal of Clinical Oncology</i> , 2005, 23, 5108-5116.	0.8	693
137	Switching to Anastrozole Versus Continued Tamoxifen Treatment of Early Breast Cancer: Preliminary Results of the Italian Tamoxifen Anastrozole Trial. <i>Journal of Clinical Oncology</i> , 2005, 23, 5138-5147.	0.8	431
138	A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer. <i>New England Journal of Medicine</i> , 2005, 353, 2747-2757.	13.9	1,465

#	ARTICLE	IF	CITATIONS
140	Aromatase Inhibitor Agents in Breast Cancer: Evolving Practices in Hormonal Therapy Treatment. <i>Oncology Nursing Forum</i> , 2005, 32, 343-353.	0.5	11
141	Prescription Pattern of Aromatase Inhibitors in the Adjuvant Setting in Germany – Final Results of a Survey Among German Breast Cancer Specialists. <i>Oncology Research and Treatment</i> , 2005, 28, 639-644.	0.8	3
142	Contralateral Prophylactic Mastectomy: Quantifying Benefits and Weighing the Harms. <i>Journal of Clinical Oncology</i> , 2005, 23, 4251-4253.	0.8	13
143	Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. <i>Lancet, The</i> , 2005, 365, 60-62.	6.3	2,078
144	Breast cancer. <i>Lancet, The</i> , 2005, 365, 1727-1741.	6.3	441
145	C?ncer de mama (y II). Estrategias terap?uticas. <i>Medicine</i> , 2005, 9, 1692-1703.	0.0	0
146	Treatment of hot flushes in breast and prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 1095-1106.	0.9	32
147	Vascular endothelial growth factor and its relationships with endogenous inhibitors in a breast cancer microenvironment manipulated by hormonal therapy: a hypothetical consideration. <i>Biomedicine and Pharmacotherapy</i> , 2005, 59, S344-S347.	2.5	5
148	Management of menopausal symptoms in patients with breast cancer: an evidence-based approach. <i>Lancet Oncology, The</i> , 2005, 6, 687-695.	5.1	77
149	Advanced disease – the optimal sequential treatment strategy. <i>European Journal of Cancer, Supplement</i> , 2005, 3, 237-245.	2.2	0
150	Adjuvant endocrine therapy options in hormone-dependent breast cancer. <i>European Journal of Cancer, Supplement</i> , 2005, 3, 247-254.	2.2	1
151	Breast cancer treatment in older women. <i>Surgical Oncology Clinics of North America</i> , 2005, 14, 85-102.	0.6	7
152	–42 A Randomized Trial of Exemestane After Two to Three Years of Tamoxifen Therapy in Postmenopausal Women With Primary Breast Cancer. <i>Breast Diseases</i> , 2005, 16, 80-81.	0.0	0
153	Aromatase inhibitors in the treatment of early and advanced breast cancer. <i>Acta Oncol?gica</i> , 2005, 44, 23-31.	0.8	27
154	Controversies in breast cancer: adjuvant and neoadjuvant therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 1055-1072.	0.9	5
155	Aromatase Inhibitors: Rationale and Use in Breast Cancer. <i>Annual Review of Medicine</i> , 2005, 56, 103-116.	5.0	49
156	American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004. <i>Journal of Clinical Oncology</i> , 2005, 23, 619-629.	0.8	810
157	Antiestrogens, Aromatase Inhibitors, and Apoptosis in Breast Cancer. <i>Vitamins and Hormones</i> , 2005, 71, 201-237.	0.7	75

#	ARTICLE	IF	CITATIONS
158	Are aromatase inhibitors superior to antiestrogens?. Journal of Steroid Biochemistry and Molecular Biology, 2005, 93, 237-247.	1.2	33
159	Vascular effects of aromatase inhibitors: Data from clinical trials. Journal of Steroid Biochemistry and Molecular Biology, 2005, 95, 143-149.	1.2	42
160	Aromatase inhibitorsâ€™ Socio-economical issues. Journal of Steroid Biochemistry and Molecular Biology, 2005, 95, 137-142.	1.2	3
161	Long-term effects of aromatase inhibitors on bone. Journal of Steroid Biochemistry and Molecular Biology, 2005, 95, 151-154.	1.2	60
162	Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer. Clinical Therapeutics, 2005, 27, 1671-1684.	1.1	30
163	New approaches to reverse resistance to hormonal therapy in human breast cancer. Drug Resistance Updates, 2005, 8, 219-233.	6.5	34
164	The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women. European Journal of Cancer, 2005, 41, 1678-1689.	1.3	42
165	Increased incidence of stroke in women with breast cancer. European Journal of Cancer, 2005, 41, 423-429.	1.3	73
166	Adjuvant endocrine therapy in postmenopausal women with early breast cancer: Where are we now?. European Journal of Cancer, 2005, 41, 1667-1677.	1.3	16
167	Aromatase inhibitor anastrozole for treating endometrial hyperplasia in obese postmenopausal women. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2005, 118, 239-240.	0.5	43
168	T1 G1 NO ER positive breast cancerâ€™ adjuvant therapy is needed. European Journal of Surgical Oncology, 2005, 31, 369-372.	0.5	2
169	Surgical decisions made by 158 women with hereditary breast cancer aged <50 years. European Journal of Surgical Oncology, 2005, 31, 1112-1118.	0.5	41
170	New developments in the treatment of postmenopausal breast cancer. Trends in Endocrinology and Metabolism, 2005, 16, 420-428.	3.1	21
171	Supplement use among men with prostate cancer. Urology, 2005, 66, 161-166.	0.5	37
172	Treatment of Bilateral Breast Cancer. , 2005, , 557-566.		0
173	Biology of Progesterone Receptor Loss in Breast Cancer and Its Implications for Endocrine Therapy. Journal of Clinical Oncology, 2005, 23, 7721-7735.	0.8	430
174	The Evolving Role of Aromatase Inhibitors in Adjuvant Breast Cancer Therapy. Clinical Breast Cancer, 2005, 6, 206-215.	1.1	7
175	Aromatase Inhibitors in the Treatment of Breast Cancer. Endocrine Reviews, 2005, 26, 331-345.	8.9	431

#	ARTICLE	IF	CITATIONS
176	Anastrozole: A New Gold Standard of Hormonal Treatment for Breast Cancer?. <i>Women's Health</i> , 2005, 1, 309-322.	0.7	2
177	Management of Hormone-Responsive Postmenopausal Breast Cancer. <i>Disease Management and Health Outcomes</i> , 2005, 13, 337-354.	0.3	1
178	Early stopping of clinical trials. <i>Breast Cancer Research</i> , 2005, 7, 181-3.	2.2	7
179	Clinical trial update: National Cancer Institute of Canada. <i>Breast Cancer Research</i> , 2005, 7, 48-51.	2.2	8
181	Effects of Switching from Tamoxifen to Anastrozole on Tamoxifen-Related Endocrine Symptoms and Quality of Life. <i>American Journal of Cancer</i> , 2006, 5, 433-440.	0.4	4
183	Cancer Drug Resistance. , 2006, , .		21
184	Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. <i>Annals of Oncology</i> , 2006, 17, vii10-vii14.	0.6	184
185	Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. <i>Lancet Oncology</i> , The, 2006, 7, 633-643.	5.1	356
187	Reducing the risk of recurrence in postmenopausal women with early breast cancer: a role for aromatase inhibitors. <i>Community Oncology</i> , 2006, 3, 275-281.	0.2	0
188	1â€“27 A Randomized Trial Comparing Axillary Dissection to No Axillary Dissection in Older Patients With T1N0 Breast Cancer: Results After 5 Years of Follow-up. <i>Breast Diseases</i> , 2006, 17, 65-66.	0.0	0
189	Steroid Receptor Imaging in Breast Cancer. <i>PET Clinics</i> , 2006, 1, 51-70.	1.5	9
190	Adjuvant Therapy for Patients Who Have Node-Positive Breast Cancer. <i>Advances in Surgery</i> , 2006, 40, 77-98.	0.6	3
191	Cardiovascular Safety Profiles of Aromatase Inhibitors. <i>Drug Safety</i> , 2006, 29, 785-801.	1.4	25
192	Exemestane as Adjuvant Treatment of Early Breast Cancer: Intergroup Exemestane Study/Tamoxifen Exemestane Adjuvant Multicenter Trials. <i>Clinical Breast Cancer</i> , 2006, 6, S41-S44.	1.1	25
193	Update on the use of aromatase inhibitors in breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 1919-1930.	0.9	51
194	Side effects of aromatase inhibitors versus tamoxifen: the patientsâ€™ perspective. <i>American Journal of Surgery</i> , 2006, 192, 496-498.	0.9	122
195	Adjuvant trials: Aromatase inhibitors in early breast cancer â€“ Are they alike?. <i>Cancer Treatment Reviews</i> , 2006, 32, 532-540.	3.4	2
196	Effects of third-generation aromatase inhibitors on bone. <i>European Journal of Cancer</i> , 2006, 42, 1044-1051.	1.3	78

#	ARTICLE	IF	CITATIONS
197	Information provision for patients by breast cancer teams about the side-effects of hormone treatments. <i>European Journal of Cancer</i> , 2006, 42, 1760-1767.	1.3	14
198	Endocrine therapy for breast cancer. <i>Update on Cancer Therapeutics</i> , 2006, 1, 285-297.	0.9	4
199	Chemoprevention of Breast Cancer in Postmenopausal Women. <i>Breast Disease</i> , 2006, 24, 79-92.	0.4	11
200	Chemoprevention of breast cancer: current status and future prospects. <i>Frontiers in Bioscience - Landmark</i> , 2006, 11, 2249.	3.0	12
201	Adjuvant Endocrine Therapy in Hormone Receptor-Positive Postmenopausal Breast Cancer: Evolution of NCCN, ASCO, and St Gallen Recommendations. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2006, 4, 971-979.	2.3	124
202	The Emerging Role of Aromatase Inhibitors in the Adjuvant Management of Breast Cancer. <i>Reviews on Recent Clinical Trials</i> , 2006, 1, 237-249.	0.4	6
203	Chemoprevention of Breast Cancer: Tamoxifen, Raloxifene, and Beyond. <i>American Journal of Therapeutics</i> , 2006, 13, 337-348.	0.5	23
204	The ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) Trial: A Step Forward in the Treatment of Early Breast Cancer. <i>Reviews on Recent Clinical Trials</i> , 2006, 1, 207-215.	0.4	9
205	Fulvestrant (â€Faslodexâ€™): Current and future role in breast cancer management. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 57, 265-273.	2.0	51
206	Joint symptoms: A practical problem of anastrozole. <i>Breast Cancer</i> , 2006, 13, 284-288.	1.3	17
207	Effect of an Aromatase Inhibitor on BMD and Bone Turnover Markers: 2-Year Results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) Trial (18233230). <i>Journal of Bone and Mineral Research</i> , 2006, 21, 1215-1223.	3.1	285
208	An association between a common variant (G972R) in the IRS-1 gene and sex hormone levels in post-menopausal breast cancer survivors. <i>Breast Cancer Research and Treatment</i> , 2006, 99, 323-331.	1.1	5
209	Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole: case report and review of the literature. <i>Breast Cancer Research and Treatment</i> , 2006, 99, 249-255.	1.1	26
212	Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis. <i>Supportive Care in Cancer</i> , 2006, 14, 917-927.	1.0	33
213	Optimizing the use of aromatase inhibitors in adjuvant therapy for postmenopausal patients with hormone-responsive early breast cancer: current and future prospects. <i>Journal of Cancer Research and Clinical Oncology</i> , 2006, 132, 343-355.	1.2	6
214	Early breast cancer. <i>International Journal of Clinical Oncology</i> , 2006, 11, 108-119.	1.0	19
216	Hot flushes in breast cancer patients. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 57, 63-77.	2.0	64
217	Serum endostatin and bFGF as predictive factors in advanced breast cancer patients treated with letrozole. <i>Clinical and Translational Oncology</i> , 2006, 8, 193-199.	1.2	15

#	ARTICLE	IF	CITATIONS
218	Histopathologic behavior of endometrial hyperplasia during tamoxifen therapy for breast cancer. <i>Gynecologic Oncology</i> , 2006, 101, 269-273.	0.6	17
219	Aromatase Inhibitors: An Overview for Surgeons. <i>Journal of the American College of Surgeons</i> , 2006, 203, 376-389.	0.2	10
220	Comparative assessment of lipid effects of endocrine therapy for breast cancer: Implications for cardiovascular disease prevention in postmenopausal women. <i>Breast</i> , 2006, 15, 301-312.	0.9	52
221	The evolving role of letrozole in the adjuvant setting: First results from the large, phase III, randomized trial BIG 1-98. <i>Breast</i> , 2006, 15, 21-29.	0.9	17
222	Inhibidores de la aromatasa y osteoporosis. <i>Revista Española De Enfermedades Metabólicas Áreas</i> , 2006, 15, 55-56.	0.0	1
223	Management of Cancer-Treatment-Induced Bone Loss in Postmenopausal Women Undergoing Adjuvant Breast Cancer Therapy: A Z-FAST Update. <i>Seminars in Oncology</i> , 2006, 33, 13-17.	0.8	52
224	The Use of Early Adjuvant Aromatase Inhibitor Therapy: Contributions From the BIG 1-98 Letrozole Trial. <i>Seminars in Oncology</i> , 2006, 33, 2-7.	0.8	7
225	Management of Postmenopausal Symptoms in Breast Cancer Survivors. <i>Seminars in Oncology</i> , 2006, 33, 696-707.	0.8	19
226	Chemoprevention of Breast Cancer for Women at High Risk. <i>Seminars in Oncology</i> , 2006, 33, 642-646.	0.8	23
227	Adjuvant Therapy With Aromatase Inhibitors for Postmenopausal Women With Early Breast Cancer: Evidence and Ongoing Controversy. <i>Seminars in Oncology</i> , 2006, 33, 672-680.	0.8	20
228	Moral reasoning as a model for health promotion. <i>Social Science and Medicine</i> , 2006, 63, 2715-2726.	1.8	14
229	The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer. <i>Cancer</i> , 2006, 106, 2576-2582.	2.0	28
230	Impact of chemotherapy regimens prior to endocrine therapy. <i>Cancer</i> , 2006, 107, 472-480.	2.0	23
231	Improvement in Dermatomyositis Rash Associated With the Use of Antiestrogen Medication. <i>Archives of Dermatology</i> , 2006, 142, 70-2.	1.7	40
232	Adherence to Endocrine Therapy for Breast Cancer. <i>Oncology</i> , 2006, 71, 1-9.	0.9	276
233	Role of Anastrozole across the Breast Cancer Continuum: From Advanced to Early Disease and Prevention. <i>Oncology</i> , 2006, 70, 1-12.	0.9	11
234	Anastrozole as an Adjuvant Endocrine Treatment for Postmenopausal Patients with Breast Cancer: Emerging Data. <i>Clinical Cancer Research</i> , 2006, 12, 1037s-1048s.	3.2	27
235	The evolving role of exemestane in the management of breast cancer. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2006, 67, 427-430.	0.2	1

#	ARTICLE	IF	CITATIONS
236	Aromatase Inhibitors and Bone Health in Women With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 5305-5312.	0.8	111
237	Chemoprevention of Breast Cancer. <i>Women's Health</i> , 2006, 2, 733-741.	0.7	11
238	Chemoprevention of Breast Cancer. <i>Women's Health</i> , 2006, 2, 853-861.	0.7	1
239	From adjuvant to preventive breast cancer treatment: bridging the gap over troubled waters. <i>Annals of Oncology</i> , 2006, 17, vii5-vii9.	0.6	0
240	Progesterone Receptor Loss Correlates with Human Epidermal Growth Factor Receptor 2 Overexpression in Estrogen Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 1013s-1018s.	3.2	54
241	Fulvestrant: Pharmacologic Profile Versus Existing Endocrine Agents for the Treatment of Breast Cancer. <i>Annals of Pharmacotherapy</i> , 2006, 40, 1572-1583.	0.9	29
243	ErbB Receptor Signaling and Therapeutic Resistance to Aromatase Inhibitors. <i>Clinical Cancer Research</i> , 2006, 12, 1008s-1012s.	3.2	43
244	Adjuvant Hormonal Therapy in Peri- and Postmenopausal Breast Cancer. <i>Oncologist</i> , 2006, 11, 718-731.	1.9	53
245	Appraising Adjuvant Aromatase Inhibitor Therapy. <i>Oncologist</i> , 2006, 11, 1058-1069.	1.9	21
246	Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology. <i>Clinical Cancer Research</i> , 2006, 12, 1245-1250.	3.2	32
247	A 62-Year-Old Woman With a New Diagnosis of Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 1434.	3.8	4
248	Aromatase Inhibitors in Breast Cancer: An Overview. <i>Oncologist</i> , 2006, 11, 553-562.	1.9	110
249	Effects of Novel Retinoic Acid Metabolism Blocking Agent (VN/14-1) on Letrozole-Insensitive Breast Cancer Cells. <i>Cancer Research</i> , 2006, 66, 11485-11493.	0.4	27
250	Adjuvant Endocrine Therapy for Postmenopausal Women with Early Breast Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 1031s-1036s.	3.2	17
251	Managing Patients on Endocrine Therapy: Focus on Quality-of-Life Issues. <i>Clinical Cancer Research</i> , 2006, 12, 1056s-1060s.	3.2	33
252	Development and Assessment of Conventional and Targeted Drug Combinations for Use in the Treatment of Aggressive Breast Cancers. <i>Current Cancer Drug Targets</i> , 2006, 6, 455-489.	0.8	36
253	Targeted Therapies in Gynecologic Cancers. <i>Current Cancer Drug Targets</i> , 2006, 6, 333-363.	0.8	38
254	Skeletal Complications of Breast Cancer Therapies. <i>Clinical Cancer Research</i> , 2006, 12, 6309s-6314s.	3.2	87

#	ARTICLE	IF	CITATIONS
255	Breast Cancer: Achievements in Adjuvant Systemic Therapies in the Pre-Genomic Era. <i>Oncologist</i> , 2006, 11, 111-125.	1.9	52
256	Initial versus sequential adjuvant aromatase inhibitor therapy: a review of the current data. <i>Current Medical Research and Opinion</i> , 2006, 22, 2479-2487.	0.9	9
257	Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids. <i>British Journal of Cancer</i> , 2006, 95, 153-158.	2.9	68
258	Anastrozole for breast cancer: recent advances and ongoing challenges. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 839-848.	1.1	4
259	Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98. <i>Journal of Clinical Oncology</i> , 2007, 25, 486-492.	0.8	835
260	How We Maintain Bone Health in Early-Stage Breast Cancer Patients on Aromatase Inhibitors. <i>Journal of Oncology Practice</i> , 2007, 3, 323-325.	2.5	2
261	Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC (Arimidex™). <i>Journal of Clinical Oncology</i> , 2007, 25, 1097-1107.	0.9	10
262	Aromatase Inhibitors and Musculoskeletal Pain in Patients With Breast Cancer. <i>Clinical Journal of Oncology Nursing</i> , 2007, 11, 433-439.	0.3	15
263	GRP78/BiP Inhibits Endoplasmic Reticulum BIK and Protects Human Breast Cancer Cells against Estrogen Starvation-Induced Apoptosis. <i>Cancer Research</i> , 2007, 67, 3734-3740.	0.4	284
264	Modeling for cost-effective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer. <i>Annals of Oncology</i> , 2007, 18, 293-298.	0.6	13
265	Definition of Clinically Distinct Molecular Subtypes in Estrogen Receptor-Positive Breast Carcinomas Through Genomic Grade. <i>Journal of Clinical Oncology</i> , 2007, 25, 1239-1246.	0.8	711
266	Optimal Use of Aromatase Inhibitors: To Lead or to Follow?. <i>Journal of Clinical Oncology</i> , 2007, 25, 2639-2641.	0.8	6
267	Optimal Treatment Strategies in Hormone-Responsive Early Breast Cancer: The Role of Aromatase Inhibitors. <i>Oncology Research and Treatment</i> , 2007, 30, 55-64.	0.8	3
268	Anastrozole-Associated Sclerosing Glomerulonephritis in a Patient with Breast Cancer. <i>Oncology</i> , 2007, 73, 415-418.	0.9	13
269	Prevalence of Joint Symptoms in Postmenopausal Women Taking Aromatase Inhibitors for Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 3877-3883.	0.8	415
270	Cardiovascular Reserve and Risk Profile of Postmenopausal Women After Chemoendocrine Therapy for Hormone Receptor-Positive Operable Breast Cancer. <i>Oncologist</i> , 2007, 12, 1156-1164.	1.9	99
271	Treatment of Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer Xenografts With Multiagent HER-Targeted Therapy. <i>Journal of the National Cancer Institute</i> , 2007, 99, 694-705.	3.0	176
272	Assessing the risk of bone fracture among postmenopausal women who are receiving adjuvant hormonal therapy for breast cancer. <i>Current Medical Research and Opinion</i> , 2007, 23, 1045-1051.	0.9	10

#	ARTICLE	IF	CITATIONS
273	The Intersection of Cancer and Aging: Establishing the Need for Breast Cancer Rehabilitation. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 866-872.	1.1	35
274	Some Aspects of the Endocrine Profile and Management of Hormone-Dependent Male Breast Cancer. <i>Oncologist</i> , 2007, 12, 798-807.	1.9	20
275	Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. <i>Annals of Oncology</i> , 2007, 18, 45-51.	0.6	90
276	Zoledronic Acid Prevents Cancer Treatment-Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group. <i>Journal of Clinical Oncology</i> , 2007, 25, 820-828.	0.8	308
278	40 Sex hormones and related compounds, including hormonal contraceptives. <i>Side Effects of Drugs Annual</i> , 2007, 29, 493-519.	0.6	0
279	High-Risk Benign Breast Lesions: Current Strategies in Management. <i>Cancer Control</i> , 2007, 14, 321-329.	0.7	25
280	Predicting the Risk of Local Recurrence in Patients With Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007, 30, 473-480.	0.6	36
281	Breast Cancer Adjuvant Endocrine Therapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2007, 13, 148-155.	1.0	14
282	The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: evidence based review. <i>Current Opinion in Oncology</i> , 2007, 19, 564-572.	1.1	11
283	Patient Centered Experiences in Breast Cancer. <i>Medical Care</i> , 2007, 45, 431-439.	1.1	214
284	Tamoxifen or Aromatase Inhibitors in Breast Cancer: Efficacy and Safety. <i>Acta Chirurgica Belgica</i> , 2007, 107, 240-256.	0.2	2
285	Anastrozole therapy for postmenopausal women with early breast cancer. <i>Expert Review of Obstetrics and Gynecology</i> , 2007, 2, 279-291.	0.4	0
286	Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. <i>Menopause</i> , 2007, 14, 995-998.	0.8	133
287	Managing High-Risk Breast Cancer. <i>Seminars in Oncology Nursing</i> , 2007, 23, 29-36.	0.7	1
288	Endocrine Effects of Breast Cancer Treatment. <i>Seminars in Oncology Nursing</i> , 2007, 23, 55-70.	0.7	9
289	Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. <i>Steroids</i> , 2007, 72, 7-25.	0.8	282
290	Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women?. <i>American Heart Journal</i> , 2007, 153, 182-188.	1.2	29
291	Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane. <i>Bone</i> , 2007, 40, 205-210.	1.4	66

#	ARTICLE	IF	CITATIONS
292	Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. <i>Bone</i> , 2007, 41, 346-352.	1.4	109
293	Primary systemic therapy for operable breast cancer: A review of clinical trials and perspectives. <i>Cancer Letters</i> , 2007, 248, 175-185.	3.2	23
294	Towards optimal endocrine therapy for hormone-sensitive breast cancer: Initial versus sequential adjuvant aromatase inhibition. <i>Cancer Letters</i> , 2007, 248, 165-174.	3.2	7
295	Summary of aromatase inhibitor trials: The past and future. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2007, 106, 40-48.	1.2	13
296	Aromatase excess in cancers of breast, endometrium and ovary. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2007, 106, 81-96.	1.2	75
298	Evaluating adjuvant hormonal therapy in early-stage breast cancer: a comparison of predictive decision models. <i>Community Oncology</i> , 2007, 4, 277-282.	0.2	0
299	Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women. <i>Breast Cancer Research</i> , 2007, 9, R52.	2.2	78
300	Estrogen Receptor Modulators and Down Regulators. <i>Drugs</i> , 2007, 67, 2335-2353.	4.9	45
301	The ATAC trial: the vanguard trial for use of aromatase inhibitors in early breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 1089-1094.	1.1	11
302	4â€“38 Randomized Trial Comparing Axillary Clearance Versus No Axillary Clearance in Older Patients With Breast Cancer: First Results of International Breast Cancer Study Group Trial 10-93. <i>Breast Diseases</i> , 2007, 17, 376-377.	0.0	0
303	Partial Breast Irradiation: Is This a Viable Option?. <i>Seminars in Breast Disease</i> , 2007, 10, 152-161.	0.0	0
304	Management of the BRCA Mutation Carrier or High-Risk Patient. <i>Clinics in Plastic Surgery</i> , 2007, 34, 15-27.	0.7	8
306	Role of Zoledronic Acid on Bone Loss by Letrozole. <i>Journal of Breast Cancer</i> , 2007, 10, 43.	0.8	0
307	Management of early breast cancer in the elderly. <i>International Journal of Cancer</i> , 2007, 120, 1155-1160.	2.3	19
308	Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma. <i>Cancer</i> , 2007, 109, 1060-1067.	2.0	30
309	Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. <i>Cancer</i> , 2007, 110, 244-254.	2.0	273
310	A method for testing a prespecified subgroup in clinical trials. <i>Statistics in Medicine</i> , 2007, 26, 3535-3549.	0.8	105
311	Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients. <i>Journal of Obstetrics and Gynaecology Research</i> , 2007, 33, 696-699.	0.6	14

#	ARTICLE	IF	CITATIONS
312	Aromatase Inhibitors in the Adjuvant Treatment of Postmenopausal Women with Early Breast Cancer: Putting Safety Issues into Perspective. <i>Breast Journal</i> , 2007, 13, 28-35.	0.4	54
313	Effectiveness of Adjuvant Tamoxifen Therapy among Older Women with Early Stage Breast Cancer. <i>Breast Journal</i> , 2007, 13, 374-382.	0.4	13
314	Quality Indicators for the Care of Breast Cancer in Vulnerable Elders. <i>Journal of the American Geriatrics Society</i> , 2007, 55, S258-69.	1.3	5
315	The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer. <i>International Journal of Clinical Practice</i> , 2007, 61, 2051-2063.	0.8	154
316	Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: Upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole. <i>Breast</i> , 2007, 16, 252-261.	0.9	18
317	Prescribing extended adjuvant letrozole. <i>Breast</i> , 2007, 16, 446-455.	0.9	3
319	Management of cancer treatment-induced bone loss in early breast and prostate cancer - a consensus paper of the Belgian Bone Club. <i>Osteoporosis International</i> , 2007, 18, 1439-1450.	1.3	107
320	Hormonal therapy for postmenopausal breast cancer: the science of sequencing. <i>Breast Cancer Research and Treatment</i> , 2007, 103, 149-160.	1.1	41
321	The effects of atamestane and toremifene alone and in combination compared with letrozole on bone, serum lipids and the uterus in an ovariectomized rat model. <i>Breast Cancer Research and Treatment</i> , 2007, 103, 293-302.	1.1	19
322	Aromatase inhibitors and cardiac toxicity: getting to the heart of the matter. <i>Breast Cancer Research and Treatment</i> , 2007, 106, 1-9.	1.1	87
323	Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (Arimidex™, Tamoxifen Alone or in Combination) trial. <i>Breast Cancer Research and Treatment</i> , 2007, 106, 229-238.	1.1	60
324	Erythema nodosum secondary to aromatase inhibitor use in breast cancer patients: case reports and review of the literature. <i>Breast Cancer Research and Treatment</i> , 2007, 106, 315-318.	1.1	27
325	Multicenter phase II trial of neoadjuvant exemestane for postmenopausal patients with hormone receptor-positive, operable breast cancer: Saitama Breast Cancer Clinical Study Group (SBCCSG-03). <i>Breast Cancer Research and Treatment</i> , 2007, 107, 87-94.	1.1	25
326	29th Annual San Antonio Breast Cancer Symposium 2006. <i>Breast Cancer Research and Treatment</i> , 2007, 103, 115-124.	1.1	1
327	Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98. <i>Breast Cancer Research and Treatment</i> , 2007, 105, 55-66.	1.1	39
328	A decade of letrozole: FACE. <i>Breast Cancer Research and Treatment</i> , 2007, 105, 67-74.	1.1	17
329	Breast cancer bone metastasis and current small therapeutics. <i>Cancer and Metastasis Reviews</i> , 2007, 25, 635-644.	2.7	44
330	Treatment strategies that effectively reduce early recurrence risk in postmenopausal women with endocrine-sensitive breast cancer: Als upfront vs. switching. <i>Journal of Cancer Research and Clinical Oncology</i> , 2007, 133, 905-916.	1.2	3

#	ARTICLE	IF	CITATIONS
331	Pilot study of acupuncture for the treatment of joint symptoms related to adjuvant aromatase inhibitor therapy in postmenopausal breast cancer patients. <i>Journal of Cancer Survivorship</i> , 2007, 1, 283-291.	1.5	74
332	The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. <i>Breast Cancer Research and Treatment</i> , 2008, 110, 189-197.	1.1	97
333	Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2008, 112, 89-98.	1.1	77
334	Are all aromatase inhibitors alike?. <i>Breast Cancer Research and Treatment</i> , 2008, 112, 35-43.	1.1	16
335	Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer. <i>Breast Cancer</i> , 2008, 15, 278-290.	1.3	35
336	Management of male breast cancer. <i>Oncology Reviews</i> , 2008, 2, 44-52.	0.8	2
337	Breast cancer chemoprevention. <i>Oncology Reviews</i> , 2008, 2, 223-228.	0.8	6
338	Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer. <i>Trials</i> , 2008, 9, 47.	0.7	15
339	Current NCI-sponsored Cooperative Group trials of endocrine therapies in breast cancer. <i>Cancer</i> , 2008, 112, 723-729.	2.0	6
340	Optimizing high-performance liquid chromatography method with fluorescence detection for quantification of tamoxifen and two metabolites in human plasma: Application to a clinical study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2008, 46, 349-355.	1.4	36
341	Design and synthesis of bisubstrate inhibitors of type 1 17 β -hydroxysteroid dehydrogenase: Overview and perspectives. <i>European Journal of Medicinal Chemistry</i> , 2008, 43, 2298-2306.	2.6	31
342	Neo-Adjuvant Hormonal Therapy. <i>Breast Journal</i> , 2008, 14, 279-283.	0.4	5
343	Clinical Trial Presentations, Agency Guidelines, and Oncology Practice: Findings from the Arimidex, Tamoxifen, Alone or in Combination Trial. <i>Clinical Breast Cancer</i> , 2008, 8, 343-346.	1.1	4
344	Aromatase inhibitors in early breast-cancer treatment: The story so far. <i>Breast</i> , 2008, 17, 2-8.	0.9	5
345	Translating trial data into patients benefits: Making the right choice. <i>Breast</i> , 2008, 17, 9-15.	0.9	10
346	Identification of CDK10 as an Important Determinant of Resistance to Endocrine Therapy for Breast Cancer. <i>Cancer Cell</i> , 2008, 13, 91-104.	7.7	202
347	The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer. <i>Breast</i> , 2008, 17, S15-S24.	0.9	4
348	2007 Highlights from: The 2007 San Antonio Breast Cancer Symposium San Antonio, TX December 13-16, 2007. <i>Clinical Breast Cancer</i> , 2008, 8, 26-32.	1.1	0

#	ARTICLE	IF	CITATIONS
349	Aromatase Inhibitors. , 2008, , .		0
351	Novel Sulfonanilide Analogs Decrease Aromatase Activity in Breast Cancer Cells: Synthesis, Biological Evaluation, and Ligand-Based Pharmacophore Identification. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 1126-1135.	2.9	26
352	Breast Cancer 2nd edition. , 2008, , .		3
354	Alterations of Sexual Function in Women With Cancer. <i>Seminars in Oncology Nursing</i> , 2008, 24, 91-101.	0.7	48
355	Aromatase inhibitors in the management of early breast cancer. <i>European Journal of Surgical Oncology</i> , 2008, 34, 1199-1207.	0.5	12
356	Comparing aromatase inhibitors and tamoxifen as neoadjuvant therapy for breast cancer. <i>Community Oncology</i> , 2008, 5, 301-305.	0.2	0
357	Als: implications for fractures in perimenopausal women with breast cancer. <i>Community Oncology</i> , 2008, 5, 625-626.	0.2	1
358	Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. <i>Lancet Oncology</i> , The, 2008, 9, 45-53.	5.1	929
359	Methodological Issues in Evaluating Cost Effectiveness of Adjuvant Aromatase Inhibitors in Early Breast Cancer. <i>Pharmacoeconomics</i> , 2008, 26, 409-423.	1.7	14
360	IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1377-1385.	1.1	52
361	Chemoprevention of breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 443-452.	1.1	28
362	Aromatase Expression in Women's Cancers. <i>Advances in Experimental Medicine and Biology</i> , 2008, 630, 112-132.	0.8	59
364	Prognostic Utility of the 21-Gene Assay in Hormone Receptor-Positive Operable Breast Cancer Compared With Classical Clinicopathologic Features. <i>Journal of Clinical Oncology</i> , 2008, 26, 4063-4071.	0.8	312
365	Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 4875-4882.	0.8	444
366	Letrozole is Superior to Anastrozole in Suppressing Breast Cancer Tissue and Plasma Estrogen Levels. <i>Clinical Cancer Research</i> , 2008, 14, 6330-6335.	3.2	121
367	Moving Research From Bench to Bedside to Community: There Is Still More to Do. <i>Journal of Clinical Oncology</i> , 2008, 26, 523-526.	0.8	13
368	Adjuvant Endocrine Therapy in Early Postmenopausal Breast Cancer. <i>Breast Care</i> , 2008, 3, 317-324.	0.8	2
369	Phase III Study Comparing Exemestane With Tamoxifen As First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. <i>Journal of Clinical Oncology</i> , 2008, 26, 4883-4890.	0.8	287

#	ARTICLE	IF	CITATIONS
370	Review of the ATAC study: tamoxifen versus anastrozole in early-stage breast cancer. Expert Review of Anticancer Therapy, 2008, 8, 1871-1881.	1.1	6
371	The breast cancer continuum in hormone-receptorâ€“positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors. Annals of Oncology, 2008, 19, 16-27.	0.6	60
372	Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer. Annals of Oncology, 2008, 19, 1669-1680.	0.6	89
373	Adherence to Oral Endocrine Therapy for Breast Cancer: A Nursing Perspective. Clinical Journal of Oncology Nursing, 2008, 12, 213-221.	0.3	52
374	Tamoxifen Use and Osteoporotic Fracture Risk: A Population-Based Analysis. Journal of Clinical Oncology, 2008, 26, 5227-5232.	0.8	65
375	Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling Analysis. Journal of the National Cancer Institute, 2008, 100, 642-648.	3.0	93
376	Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230. Journal of Clinical Oncology, 2008, 26, 1051-1057.	0.8	363
377	Update: A 62-Year-Old Woman With a New Diagnosis of Breast Cancer. JAMA - Journal of the American Medical Association, 2008, 299, 1055.	3.8	0
378	Cancer Treatmentâ€“Induced Bone Loss: Pathophysiology and Clinical Perspectives. Oncologist, 2008, 13, 187-195.	1.9	67
381	Outcome Analysis of Breast Cancer Patients Receiving Breast-Conserving Surgery in Southern Italy. Journal of Chemotherapy, 2008, 20, 269-277.	0.7	0
382	4. Treatment of Secondary Osteoporoses. The Journal of the Japanese Society of Internal Medicine, 2008, 97, 2463-2468.	0.0	0
383	Bone Mineral Density and Bone Turnover in Postmenopausal Women Treated for Breast Cancer. Cancer Nursing, 2008, 31, 182-190.	0.7	17
384	Neoadjuvant endocrine therapy for breast cancer: past, present and future. Anti-Cancer Drugs, 2008, 19, 339-347.	0.7	14
385	Long-term safety of aromatase inhibitors in the treatment of breast cancer. Therapeutics and Clinical Risk Management, 2008, Volume 4, 189-204.	0.9	46
387	Prevention of Bone Loss After Withdrawal of Tamoxifen. Endocrine Practice, 2008, 14, 162-167.	1.1	12
388	Osteoporosis Associated with Cancer Therapy. , 2008, , 1337-1374.		0
389	Safety of Adjuvant Endocrine Therapies in Hormone Receptorâ€“Positive Early Breast Cancer tissues. Current Oncology, 2009, 16, 14-23.	0.9	17
390	Side effects of anastrozole in the experimental pre-menopausal mammary carcinogenesis. Neoplasma, 2009, 56, 124-129.	0.7	8

#	ARTICLE	IF	CITATIONS
391	An Updated Review on the Efficacy of Adjuvant Endocrine Therapies in Hormone Receptor-Positive Early Breast Cancer. <i>Current Oncology</i> , 2009, 16, 1-13.	0.9	4
392	Estrogen Receptor in Breast Cancer and Resistance to Tamoxifen. <i>Journal of Clinical Oncology</i> , 2009, 27, 3413-3415.	0.8	10
393	Current indications for post-mastectomy radiation. <i>International Seminars in Surgical Oncology</i> , 2009, 6, 5.	1.1	16
394	[11C]Choline Positron Emission Tomography in Estrogen Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 5503-5510.	3.2	48
395	Ductal Intraepithelial Neoplasia: Postsurgical Outcome for 1,267 Women Cared for in One Single Institution over 10 Years. <i>Oncologist</i> , 2009, 14, 201-212.	1.9	21
397	Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer. <i>Breast</i> , 2009, 18, 78-83.	0.9	20
398	Implementing a Low-Fat Eating Plan in the Women's Intervention Nutrition Study. <i>Journal of the American Dietetic Association</i> , 2009, 109, 688-696.	1.3	50
399	Update of the BIG 1-98 Trial: Where do we stand?. <i>Breast</i> , 2009, 18, S78-S82.	0.9	14
400	Biological profile of oestrogen receptor positive primary breast cancers in the elderly and response to primary endocrine therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 72, 76-82.	2.0	10
401	Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 603-609.	1.1	75
402	The Expanding Use of Third-Generation Aromatase Inhibitors: What the General Internist Needs to Know. <i>Journal of General Internal Medicine</i> , 2009, 24, 383-388.	1.3	20
404	Safety, Tolerability and Pharmacokinetics of TAS108, a Novel Anti-Oestrogen, in Healthy Post-Menopausal Japanese Women: A Phase I Single Oral Dose Study. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2009, 104, 352-359.	1.2	7
405	Managing biomedical uncertainty: the technoscientific illness identity. <i>Sociology of Health and Illness</i> , 2009, 31, 1059-1076.	1.1	42
406	Phase 3 Trials of Aromatase Inhibitors for Breast Cancer Prevention. <i>Annals of the New York Academy of Sciences</i> , 2009, 1155, 141-161.	1.8	19
407	Regulation of Aromatase Expression in Breast Cancer Tissue. <i>Annals of the New York Academy of Sciences</i> , 2009, 1155, 121-131.	1.8	70
408	Breast cancer subtypes and molecular biomarkers. <i>Diagnostic Histopathology</i> , 2009, 15, 485-489.	0.2	11
409	Lead optimization of COX-2 inhibitor nimesulide analogs to overcome aromatase inhibitor resistance in breast cancer cells. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 6733-6735.	1.0	21
410	A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial. <i>American Journal of Obstetrics and Gynecology</i> , 2009, 200, 80.e1-80.e7.	0.7	19

#	ARTICLE	IF	CITATIONS
411	Effects of hormonal treatment on lipids in patients with cancer. <i>Cancer Treatment Reviews</i> , 2009, 35, 175-184.	3.4	48
412	Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2009, 114, 8-20.	1.2	73
413	Comparing the effects of atamestane, toremifene and tamoxifen alone and in combination, on bone, serum lipids and uterus in ovariectomized rats. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2009, 113, 233-240.	1.2	7
414	Treatment of established breast cancer in post-menopausal women: Role of aromatase inhibitors. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2009, 7, 42-55.	0.8	6
415	Exemestane. <i>Drugs</i> , 2009, 69, 889-918.	4.9	35
416	Update on the use of aromatase inhibitors in early-stage breast cancer. <i>Breast Cancer Research</i> , 2009, 11, 211.	2.2	6
417	Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy. <i>Breast Cancer Research</i> , 2009, 11, R35.	2.2	31
418	Are we HER-ting for innovation in neoadjuvant breast cancer trial design?. <i>Breast Cancer Research</i> , 2009, 11, 201.	2.2	9
419	Endocrine therapy for the treatment of postmenopausal women with breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 187-198.	1.1	17
420	Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 1435-1447.	0.9	26
421	Vitamin D Insufficiency and Musculoskeletal Symptoms in Breast Cancer Survivors on Aromatase Inhibitor Therapy. <i>Cancer Nursing</i> , 2009, 32, 143-150.	0.7	46
422	Women's Health, Breast Health. <i>Obstetrical and Gynecological Survey</i> , 2009, 64, 469-480.	0.2	6
423	NCCN Task Force Report: Bone Health in Cancer Care. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, S-1-S-32.	2.3	163
424	Patient and Provider Determinants Associated With the Prescription of Adjuvant Hormonal Therapies Following a Diagnosis of Breast Cancer in Medicaid-Enrolled Patients. <i>Journal of the National Medical Association</i> , 2009, 101, 1112-1118.	0.6	2
425	Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer. <i>Yearbook of Endocrinology</i> , 2010, 2010, 234-236.	0.0	0
426	Translational Research in Surgical Disease. <i>Archives of Surgery</i> , 2010, 145, 187.	2.3	3
427	Breast Cancer Risk Reduction. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 1112-1146.	2.3	34
428	Adverse events and bone health during anastrozole therapy in postmenopausal Japanese breast cancer patients. <i>Breast Cancer</i> , 2010, 17, 212-217.	1.3	9

#	ARTICLE	IF	CITATIONS
429	Pharmacogenomics of Tamoxifen: Ready for Prime Time?. <i>Current Breast Cancer Reports</i> , 2010, 2, 32-41.	0.5	1
430	Role of aromatase inhibitors in the upfront adjuvant hormonal therapy of postmenopausal patients with breast cancer. <i>Indian Journal of Surgical Oncology</i> , 2010, 1, 19-26.	0.3	1
431	RANK Ligand: Effects of Inhibition. <i>Current Oncology Reports</i> , 2010, 12, 80-86.	1.8	13
432	Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: a systematic review. <i>Breast Cancer Research and Treatment</i> , 2010, 121, 273-279.	1.1	30
433	Breast Cancer Prevention Trials: Large and Small Trials. <i>Seminars in Oncology</i> , 2010, 37, 367-383.	0.8	18
434	The Use of Animal Models for Cancer Chemoprevention Drug Development. <i>Seminars in Oncology</i> , 2010, 37, 327-338.	0.8	49
435	Breast Cancer Follow-Up: Strategies for Successful Collaboration between Cancer Care Specialists and Primary Care Providers. <i>Journal for Nurse Practitioners</i> , 2010, 6, 452-463.	0.4	0
436	Effects of a Structured Weight-Bearing Exercise Program on Bone Metabolism Among Breast Cancer Survivors: A Feasibility Trial. <i>Clinical Breast Cancer</i> , 2010, 10, 224-229.	1.1	63
437	Adjuvant therapy for postmenopausal women with endocrine-sensitive breast cancer. <i>Breast</i> , 2010, 19, 69-75.	0.9	12
438	Aromatase inhibitors versus tamoxifen as adjuvant hormonal therapy for oestrogen sensitive early breast cancer in post-menopausal women: Meta-analyses of monotherapy, sequenced therapy and extended therapy. <i>Breast</i> , 2010, 19, 76-83.	0.9	38
439	Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 73, 156-166.	2.0	122
440	Women's perceptions and experience of adjuvant tamoxifen therapy account for their adherence: breast cancer patients' point of view. <i>Psycho-Oncology</i> , 2010, 19, 472-479.	1.0	69
441	Breast and prostate cancer: more similar than different. <i>Nature Reviews Cancer</i> , 2010, 10, 205-212.	12.8	212
442	Current and emerging treatment strategies for breast cancer-induced bone loss. <i>Breast Cancer: Targets and Therapy</i> , 2010, 2, 71.	1.0	0
443	Critical appraisal of denosumab in the treatment and prevention of postmenopausal osteoporosis and bone loss in patients undergoing hormone ablation. <i>Orthopedic Research and Reviews</i> , 0, Volume 2, 49-69.	0.7	0
444	Healthcare costs in postmenopausal women with hormone-positive metastatic breast cancer. <i>Journal of Medical Economics</i> , 2010, 13, 691-697.	1.0	8
445	Simultaneous targeting of estrogen receptor and HER2 in breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1255-1263.	1.1	14
446	Early recurrence risk: aromatase inhibitors versus tamoxifen. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1239-1253.	1.1	7

#	ARTICLE	IF	CITATIONS
447	Drug-induced osteoporosis in the older adult. <i>Aging Health</i> , 2010, 6, 501-518.	0.3	12
448	Adjuvant Trastuzumab for HER2-Positive Early Breast Cancer. <i>Clinical Journal of Oncology Nursing</i> , 2010, 14, 326-336.	0.3	2
449	Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR+ early-stage breast cancer. <i>Current Medical Research and Opinion</i> , 2010, 26, 2315-2328.	0.9	6
450	Targeting RANK/RANKL in the Treatment of Solid Tumours and Myeloma. <i>Current Pharmaceutical Design</i> , 2010, 16, 1272-1283.	0.9	17
451	Guidelines for Osteoprotection in Breast Cancer Patients on an Aromatase Inhibitor. <i>Breast Care</i> , 2010, 5, 290-296.	0.8	9
453	Effect of aromatase inhibitors on the lipid profile of postmenopausal breast cancer patients. <i>Clinical Lipidology</i> , 2010, 5, 245-254.	0.4	4
454	Effect of Body Mass Index on Recurrences in Tamoxifen and Anastrozole Treated Women: An Exploratory Analysis From the ATAC Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 3411-3415.	0.8	271
456	Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. <i>Lancet Oncology</i> , The, 2010, 11, 1135-1141.	5.1	1,017
457	Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. <i>Breast Cancer Research</i> , 2010, 12, R24.	2.2	70
458	Management of Bone Disease in Patients Undergoing Hormonal Therapy for Breast Cancer. <i>Endocrinology and Metabolism Clinics of North America</i> , 2011, 40, 549-562.	1.2	9
459	Putting the Cardiovascular Safety of Aromatase Inhibitors in Patients with Early Breast Cancer into Perspective. <i>Drug Safety</i> , 2011, 34, 1125-1149.	1.4	20
460	Endocrine Therapy of Breast Cancer. <i>Current Medicinal Chemistry</i> , 2011, 18, 513-522.	1.2	140
461	Exemestane for Breast-Cancer Prevention in Postmenopausal Women. <i>New England Journal of Medicine</i> , 2011, 364, 2381-2391.	13.9	847
462	New and translational perspectives of oestrogen deprivation in breast cancer. <i>Molecular and Cellular Endocrinology</i> , 2011, 340, 137-141.	1.6	9
463	Bone health and prevention of treatment-induced osteoporosis in oncology. , 2011, , 438-447.		0
464	Bone tissue as the site of action of oncological drugs. <i>Wspolczesna Onkologia</i> , 2011, 3, 147-154.	0.7	0
465	Pain and Palliative Care Needs of Cancer Survivors. <i>Journal of Hospice and Palliative Nursing</i> , 2011, 13, 202-207.	0.5	3
466	Aromatase inhibitor-induced skin adverse reactions: exemestane-related cutaneous vasculitis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 596-598.	1.3	34

#	ARTICLE	IF	CITATIONS
467	Chronic treatment-related pain in cancer survivors. <i>Pain</i> , 2011, 152, S84-S89.	2.0	73
468	Voltammetric quantification of tamoxifen. <i>Drug Testing and Analysis</i> , 2011, 3, 743-747.	1.6	12
469	Androgen receptor genotypes predict response to endocrine treatment in breast cancer patients. <i>British Journal of Cancer</i> , 2011, 105, 1676-1683.	2.9	29
470	Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 869-878.	1.1	80
471	Associations of physical activity with quality of life and functional ability in breast cancer patients during active adjuvant treatment: the Pathways Study. <i>Breast Cancer Research and Treatment</i> , 2011, 129, 521-529.	1.1	28
472	Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial. <i>Breast Cancer Research and Treatment</i> , 2011, 129, 107-116.	1.1	108
473	Neoadjuvant endocrine treatment of women with breast cancer. <i>Oncology Reviews</i> , 2011, 5, 157-166.	0.8	0
474	Update on adjuvant hormonal treatment of early breast cancer. <i>Advances in Therapy</i> , 2011, 28, 1-18.	1.3	8
475	Bone Targeted Therapies in Early Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2011, 12, 412-423.	1.3	5
476	Changes in Breast Density and Circulating Estrogens in Postmenopausal Women Receiving Adjuvant Anastrozole. <i>Cancer Prevention Research</i> , 2011, 4, 1993-2001.	0.7	23
477	Perspectives on Adherence and Persistence With Oral Medications for Cancer Treatment. <i>Journal of Oncology Practice</i> , 2011, 7, 65-67.	2.5	40
478	Cancer Therapy Associated Bone Loss: Implications for Hip Fractures in Mid-Life Women with Breast Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 560-568.	3.2	40
479	Current role and safety profile of aromatase inhibitors in early breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1253-1263.	1.1	29
480	Chemoprevention of Breast Cancer: The Paradox of Evidence versus Advocacy Inaction. <i>Cancers</i> , 2012, 4, 1146-1160.	1.7	8
481	CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2012, 104, 452-460.	3.0	247
482	Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index. <i>British Journal of Cancer</i> , 2012, 107, 1815-1819.	2.9	24
483	Economic Evaluation of Genomic Test-“Directed Chemotherapy for Early-Stage Lymph Node-“Positive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2012, 104, 56-66.	3.0	75
484	Practice Bulletin No. 126. <i>Obstetrics and Gynecology</i> , 2012, 119, 666-682.	1.2	50

#	ARTICLE	IF	CITATIONS
485	Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04). <i>Breast Cancer Research and Treatment</i> , 2012, 133, 227-236.	1.1	42
486	Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 1569-1577.	1.2	5
487	Chemoprevention of Breast Cancer. <i>Women's Health</i> , 2012, 8, 635-646.	0.7	6
488	Aromatase, breast cancer and obesity: a complex interaction. <i>Trends in Endocrinology and Metabolism</i> , 2012, 23, 83-89.	3.1	167
489	Preventive Therapy for Breast Cancer. <i>Current Oncology Reports</i> , 2012, 14, 568-573.	1.8	5
490	Reviewing the Cost-Effectiveness of Endocrine Early Breast Cancer Therapies: Influence of Differences in Modeling Methods on Outcomes. <i>Value in Health</i> , 2012, 15, 94-105.	0.1	16
491	Animal Models for Breast Cancer Prevention Research. , 2012, , 497-526.		1
492	Women's Experiences With Antiestrogen Therapy to Treat Breast Cancer. <i>Oncology Nursing Forum</i> , 2012, 39, 70-77.	0.5	20
493	Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2012, 4, 91.	1.0	10
494	Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 727-734.	1.1	47
495	Phase II Trial of Exemestane in Combination With Fulvestrant in Postmenopausal Women With Advanced, Hormone-Responsive Breast Cancer. <i>Clinical Breast Cancer</i> , 2012, 12, 151-156.	1.1	7
496	The biology of progesterone receptor in the normal mammary gland and in breast cancer. <i>Molecular and Cellular Endocrinology</i> , 2012, 357, 4-17.	1.6	138
497	Ductal carcinoma in situ (DCIS) of the breast: Perspectives on biology and controversies in current management. <i>Journal of Surgical Oncology</i> , 2012, 105, 212-220.	0.8	15
498	Synchronous and metachronous bilateral breast cancer: a long-term single-institution experience. <i>Medical Oncology</i> , 2012, 29, 16-24.	1.2	36
499	Breast Cancer Risk Assessment, Prevention, and the Future. <i>Obstetrics and Gynecology Clinics of North America</i> , 2013, 40, 525-549.	0.7	9
500	Adjuvant Aromatase Inhibitor Therapy in Patients with Stage I Breast Cancer at a Regional Oncology Center in Israel: Implementation of a 'Switching' Policy in Postmenopausal Patients after Initial Tamoxifen. <i>Oncology</i> , 2013, 85, 145-152.	0.9	2
501	The Inhibitory Effects of the Standardized Extracts of <i>Ginkgo biloba</i> on Aromatase Activity in JEG-3 Human Choriocarcinoma Cells. <i>Phytotherapy Research</i> , 2013, 27, 1756-1762.	2.8	7
502	Breast Cancer Survivorship Issues. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 805-827.	0.9	54

#	ARTICLE	IF	CITATIONS
503	Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study. <i>Breast Cancer Research and Treatment</i> , 2013, 140, 385-395.	1.1	37
504	Comparison of the effects of aromatase inhibitors and tamoxifen on radiation-induced lung toxicity: results of an experimental study. <i>Supportive Care in Cancer</i> , 2013, 21, 811-817.	1.0	19
505	The role of adjuvant radiation treatment in older women with early breast cancer. <i>Journal of Geriatric Oncology</i> , 2013, 4, 402-412.	0.5	5
506	Locoregional recurrence in patients with HER2 positive breast cancer. <i>Breast</i> , 2013, 22, 856-862.	0.9	11
507	Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment. <i>European Journal of Cancer, Supplement</i> , 2013, 11, 3-22.	2.2	6
508	Adjuvant Systemic Therapies in Breast Cancer. <i>Surgical Clinics of North America</i> , 2013, 93, 473-491.	0.5	55
509	Detection of anticancer drug tamoxifen using biosensor based on polyaniline probe modified with horseradish peroxidase. <i>Materials Science and Engineering C</i> , 2013, 33, 583-587.	3.8	39
510	Cancer Treatment-Induced Bone Loss in Patients with Breast Cancer. , 2013, , 1445-1454.		0
511	Isolated Uterine Metastasis of Invasive Ductal Carcinoma. <i>Case Reports in Oncological Medicine</i> , 2013, 2013, 1-3.	0.2	16
512	Breast cancer and osteoporosis. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2013, 20, 532-538.	1.2	15
513	Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27â€”A Randomized Controlled Phase III Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 1398-1404.	0.8	218
514	A Polymorphism at the 3'-UTR Region of the Aromatase Gene Is Associated with the Efficacy of the Aromatase Inhibitor, Anastrozole, in Metastatic Breast Carcinoma. <i>International Journal of Molecular Sciences</i> , 2013, 14, 18973-18988.	1.8	31
515	Tailoring treatment for ductal intraepithelial neoplasia of the breast according to Ki-67 and molecular phenotype. <i>British Journal of Cancer</i> , 2013, 108, 1593-1601.	2.9	38
516	Effect of Endocrine Therapy on Quality of Life and Cognitive Functions in Patients with Breast Cancer. <i>Breast Care</i> , 2013, 8, 128-132.	0.8	12
517	NCCN Task Force Report: Bone Health in Cancer Care. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, S-1-S-50.	2.3	245
518	Tamoxifen and Depression: Drug Interactions in Breast Cancer. <i>The Consultant Pharmacist</i> , 2013, 28, 584-591.	0.4	5
519	Patterns of use of oral adjuvant endocrine therapy in Australian breast cancer survivors 5 years from diagnosis. <i>Menopause</i> , 2013, 20, 721-726.	0.8	8
520	Understanding discontinuation of oral adjuvant endocrine therapy by women with hormone receptorâ€”positive invasive breast cancer nearly 4 years from diagnosis. <i>Menopause</i> , 2013, 20, 15-21.	0.8	20

#	ARTICLE	IF	CITATIONS
521	Expression of Estrogen-Related Gene Markers in Breast Cancer Tissue Predicts Aromatase Inhibitor Responsiveness. PLoS ONE, 2013, 8, e77543.	1.1	5
522	Pathogenesis, prevention, diagnosis and treatment of breast cancer. World Journal of Clinical Oncology, 2014, 5, 283.	0.9	184
523	Preventative therapies for healthy women at high risk of breast cancer. Cancer Management and Research, 2014, 6, 423.	0.9	21
524	Effects of Tamoxifen and Aromatase Inhibitors on Breast Tissue Enhancement in Dynamic Contrast-enhanced Breast MR Imaging: A Longitudinal Intraindividual Cohort Study. Radiology, 2014, 271, 45-55.	3.6	54
525	Omics Approaches in Breast Cancer. , 2014, , .		10
526	Second malignancies after breast cancer: The impact of adjuvant therapy. Molecular and Clinical Oncology, 2014, 2, 331-336.	0.4	26
527	Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial. Lancet Oncology, The, 2014, 15, 474-482.	5.1	45
528	Systemic Therapy of Bone Metastases. Cancer Metastasis - Biology and Treatment, 2014, , 247-273.	0.1	0
529	Determinants of newly diagnosed comorbidities among breast cancer survivors. Journal of Cancer Survivorship, 2014, 8, 384-393.	1.5	21
530	A multicenter prospective study to evaluate bone fracture related to adjuvant anastrozole in Japanese postmenopausal women with breast cancer: two-year interim analysis of Saitama Breast Cancer Clinical Study Group (SBCCSG-06). International Journal of Clinical Oncology, 2014, 19, 68-73.	1.0	1
531	Understanding response and resistance to oestrogen deprivation in ER-positive breast cancer. Molecular and Cellular Endocrinology, 2014, 382, 683-694.	1.6	45
533	The therapeutic significance of aromatase inhibitors in endometrial carcinoma. Gynecologic Oncology, 2014, 134, 190-195.	0.6	38
534	Tracking progesterone receptor-mediated actions in breast cancer. , 2014, 142, 114-125.		63
535	Bone Metastases. Cancer Metastasis - Biology and Treatment, 2014, , .	0.1	5
536	Estrogen Response element-GFP (ERE-GFP) introduced MCF-7 cells demonstrated the coexistence of multiple estrogen-deprivation resistant mechanisms. Journal of Steroid Biochemistry and Molecular Biology, 2014, 139, 61-72.	1.2	20
537	Prise en charge du cancer du sein, avancées et perspectives. Medecine Nucleaire, 2014, 38, 299-302.	0.2	0
538	Early discontinuation of endocrine therapy for breast cancer: who is at risk in clinical practice?. SpringerPlus, 2014, 3, 282.	1.2	36
539	Hormonal prevention of breast cancer. Annales D'Endocrinologie, 2014, 75, 148-155.	0.6	2

#	ARTICLE	IF	CITATIONS
540	The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer. <i>Breast</i> , 2014, 23, 201-208.	0.9	57
542	The effect of anastrozole on bone mineral density during the first 5 years of adjuvant treatment in postmenopausal women with early breast cancer. <i>SpringerPlus</i> , 2015, 4, 303.	1.2	5
543	Validity and reliability of the Patient-Reported Arthralgia Inventory: validation of a newly-developed survey instrument to measure arthralgia. <i>Patient Related Outcome Measures</i> , 2015, 6, 205.	0.7	5
544	Management of early breast cancer in older women: from screening to treatment. <i>Breast Cancer: Targets and Therapy</i> , 2015, 7, 165.	1.0	14
545	Adjuvant Aromatase Inhibitor Therapy in Early Breast Cancer: What Factors Lead Patients to Discontinue Treatment?. <i>Tumori</i> , 2015, 101, 469-473.	0.6	36
546	Costâ€“Utility of Adjuvant Zoledronic Acid in Patients with Breast Cancer and Low Estrogen Levels. <i>Current Oncology</i> , 2015, 22, 246-253.	0.9	0
547	Tai Chi Chuan Exercise for Patients with Breast Cancer: A Systematic Review and Meta-Analysis. <i>Evidence-based Complementary and Alternative Medicine</i> , 2015, 2015, 1-15.	0.5	43
548	The effect of YOCASÂ© yoga for musculoskeletal symptoms among breast cancer survivors on hormonal therapy. <i>Breast Cancer Research and Treatment</i> , 2015, 150, 597-604.	1.1	63
549	Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 533-541.	1.1	31
550	Mechanisms of hormonal therapy resistance in breast cancer. <i>International Journal of Clinical Oncology</i> , 2015, 20, 262-267.	1.0	14
552	Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. <i>Lancet, The</i> , 2015, 386, 1341-1352.	6.3	1,072
553	Economic Evaluation of Hormonal Therapies for Postmenopausal Women with Estrogen Receptorâ€“Positive Early Breast Cancer in Canada. <i>Current Oncology</i> , 2015, 22, 84-96.	0.9	14
555	Tamoxifen (Selective Estrogen-Receptor Modulators) and Aromatase Inhibitors as Potential Perioperative Thrombotic Risk Factors in Free Flap Breast Reconstruction. <i>Plastic and Reconstructive Surgery</i> , 2015, 135, 670e-679e.	0.7	33
556	Obesity and male breast cancer: provocative parallels?. <i>BMC Medicine</i> , 2015, 13, 134.	2.3	26
557	Neoadjuvant endocrine therapy: Patient selection, treatment duration and surrogate endpoints. <i>Breast</i> , 2015, 24, S78-S83.	0.9	22
558	Progesterone receptor loss identifies hormone receptor-positive and HER2-negative breast cancer subgroups at higher risk of relapse: a retrospective cohort study. <i>OncoTargets and Therapy</i> , 2016, 9, 1707.	1.0	9
559	Aromatase inhibitors. , 2016, , 690-695.		0
560	Tamoxifen in men: a review of adverse events. <i>Andrology</i> , 2016, 4, 776-788.	1.9	48

#	ARTICLE	IF	CITATIONS
561	Progesterone Receptor Signaling Mechanisms. <i>Journal of Molecular Biology</i> , 2016, 428, 3831-3849.	2.0	153
562	Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases. <i>Annals of Surgery</i> , 2016, 264, 413-420.	2.1	392
563	A new Suzuki synthesis of triphenylethylenes that inhibit aromatase and bind to estrogen receptors $\hat{1}\pm$ and $\hat{1}^2$. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 5400-5409.	1.4	16
564	Treatment with <i>Ruta graveolens</i> 5CH and <i>Rhus toxicodendron</i> 9CH may reduce joint pain and stiffness linked to aromatase inhibitors in women with early breast cancer: results of a pilot observational study. <i>Homeopathy</i> , 2016, 105, 299-308.	0.5	18
565	Elevated incidence of fractures in women with invasive breast cancer. <i>Osteoporosis International</i> , 2016, 27, 499-507.	1.3	19
566	Women, thrombosis, and cancer: A gender-specific analysis. <i>Thrombosis Research</i> , 2017, 151, S21-S29.	0.8	11
567	Extended Endocrine Therapy: Is 5ÅYears Enough?. <i>Current Oncology Reports</i> , 2017, 19, 16.	1.8	5
569	Extended Adjuvant Aromatase Inhibitor Therapy in Post-Menopausal Women. <i>Current Breast Cancer Reports</i> , 2017, 9, 236-241.	0.5	4
570	IPET study: an FLT-PET window study to assess the activity of the steroid sulfatase inhibitor irosustat in early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 527-539.	1.1	24
571	Polymorphisms in <i>ABC1</i> and <i>CYP19A1</i> genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 562-571.	1.1	23
572	Cardiotoxicity of Aromatase Inhibitors in Breast Cancer Patients. <i>Clinical Breast Cancer</i> , 2017, 17, 11-17.	1.1	60
573	Bone Density Screening in Postmenopausal Women With Early-Stage Breast Cancer Treated With Aromatase Inhibitors. <i>Journal of Oncology Practice</i> , 2017, 13, e505-e515.	2.5	12
574	Prevalence and determinants of adherence to oral adjuvant endocrine therapy among breast cancer patients in Singapore. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2017, 4, 283-289.	0.7	16
575	Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03). <i>Breast Cancer Research and Treatment</i> . 2018, 169, 537-548.	1.1	58
576	Cancer survivors: An expanding population with an increased cardiometabolic risk. <i>Diabetes Research and Clinical Practice</i> , 2018, 143, 432-442.	1.1	27
577	Aromatase inhibitors are associated with a higher fracture risk than tamoxifen: a systematic review and meta-analysis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2018, 10, 71-90.	1.2	43
578	Primary Prevention of Breast Cancer. , 2018, , 219-236.e3.		2
579	Endocrine Therapy for Breast Cancer. , 2018, , 907-923.e6.		2

#	ARTICLE	IF	CITATIONS
580	Bilateral Breast Cancer. , 2018, , 967-973.e2.		1
581	Therapeutic approaches for protecting bone health in patients with breast cancer. <i>Breast</i> , 2018, 37, 28-35.	0.9	16
582	Effect of denosumab administration on low bone mineral density (T-score $\hat{\sim}$ 1.0 to $\hat{\sim}$ 2.5) in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer. <i>Journal of Bone and Mineral Metabolism</i> , 2018, 36, 716-722.	1.3	12
583	Current Strategies of Endocrine Therapy in Elderly Patients with Breast Cancer. <i>BioMed Research International</i> , 2018, 2018, 1-12.	0.9	12
584	Hypoxia and Hormone-Mediated Pathways Converge at the Histone Demethylase KDM4B in Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 240.	1.8	29
585	Clinical Benefits of Acupuncture for the Reduction of Hormone Therapy-Related Side Effects in Breast Cancer Patients: A Systematic Review. <i>Integrative Cancer Therapies</i> , 2018, 17, 602-618.	0.8	20
586	Fracture Risk in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study. <i>Oncologist</i> , 2019, 24, 1432-1438.	1.9	10
587	Radiation Therapy Without Hormone Therapy for Women Age 70 or Above with Low-Risk Early Breast Cancer: A Microsimulation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 296-306.	0.4	37
588	Aromatase inhibitors and risk of cardiovascular events in breast cancer patients: a systematic review and meta-analysis. <i>BMC Pharmacology & Toxicology</i> , 2019, 20, 62.	1.0	6
589	Women, thrombosis, and cancer. <i>Thrombosis Research</i> , 2019, 181, S47-S53.	0.8	7
590	ER \pm -targeted endocrine therapy, resistance and the role of GPER. <i>Steroids</i> , 2019, 152, 108493.	0.8	18
591	Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 785-794.	1.1	50
592	Deuterium Depleted Water Inhibits the Proliferation of Human MCF7 Breast Cancer Cell Lines by Inducing Cell Cycle Arrest. <i>Nutrition and Cancer</i> , 2019, 71, 1019-1029.	0.9	19
593	Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia. <i>Bone</i> , 2019, 124, 83-88.	1.4	9
594	Estrogens and breast cancer: Mechanisms involved in obesity-related development, growth and progression. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2019, 189, 161-170.	1.2	108
598	Changes in Bone Mineral Density in Women With Breast Cancer. <i>Cancer Nursing</i> , 2019, 42, 164-172.	0.7	7
599	Influence of chemotherapy and endocrine treatment on fractures in postmenopausal women with breast cancer – a retrospective cohort study. <i>Journal of Bone Oncology</i> , 2020, 22, 100292.	1.0	7
600	Reconsidering Aromatase for Breast Cancer Treatment: New Roles for an Old Target. <i>Molecules</i> , 2020, 25, 5351.	1.7	19

#	ARTICLE	IF	CITATIONS
601	Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies. <i>ESMO Open</i> , 2020, 5, e000743.	2.0	7
603	Cost-effectiveness analysis of endocrine therapy alone versus partial-breast irradiation alone versus combined treatment for low-risk hormone-positive early-stage breast cancer in women aged 70 years or older. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 355-365.	1.1	15
604	Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 259-266.	1.1	0
605	Quantifying the Mitigating Effects of Whole-Breast Radiotherapy and Systemic Treatments on Regional Recurrence Incidence Among Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2020, 27, 3402-3411.	0.7	5
606	Prolonged Time to Adjuvant Chemotherapy Initiation Was Associated with Worse Disease Outcome in Triple Negative Breast Cancer Patients. <i>Scientific Reports</i> , 2020, 10, 7029.	1.6	14
607	Cardiotoxicity of Use of Sequential Aromatase Inhibitors in Women With Breast Cancer. <i>American Journal of Epidemiology</i> , 2020, 189, 1086-1095.	1.6	13
608	Estrogen receptor-positive (ER+) breast cancer treatment: Are multi-target compounds the next promising approach?. <i>Biochemical Pharmacology</i> , 2020, 177, 113989.	2.0	35
609	Clinical Outcomes Following Letrozole Treatment according to Estrogen Receptor Expression in Postmenopausal Women: LETTER Study (KBCSG-006). <i>Journal of Breast Cancer</i> , 2021, 24, 164.	0.8	2
610	Pharmacogenetics of tamoxifen therapy in Asian populations: from genetic polymorphism to clinical outcomes. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 1095-1111.	0.8	8
611	Palliative treatment of endometrial cancer: what is the role of anastrozole in elderly women?. <i>BMC Palliative Care</i> , 2021, 20, 28.	0.8	1
612	Quality of Life (QoL) in Postmenopausal Breast Cancer Patients Receiving Adjuvant Hormonal Therapy. <i>Indian Journal of Surgery</i> , 0, , 1.	0.2	1
613	Concordance of the molecular subtype classification between core needle biopsy and surgical specimen in primary breast cancer. <i>Archives of Gynecology and Obstetrics</i> , 2021, 304, 783-790.	0.8	5
614	Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 409-424.	1.6	33
615	Interactions between cardiology and oncology drugs in precision cardio-oncology. <i>Clinical Science</i> , 2021, 135, 1333-1351.	1.8	7
616	Further Evidence That OPC rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 662734.	1.1	8
617	Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early-Stage Breast Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1038-1049.	2.3	5
618	Health-Related Quality of Life Among Patients With HR+/HER2- Early Breast Cancer. <i>Clinical Therapeutics</i> , 2021, 43, 1228-1244.e4.	1.1	11
619	Cost-Effectiveness Analysis of No Adjuvant Therapy Versus Partial Breast Irradiation Alone Versus Combined Treatment for Treatment of Low-Risk DCIS: A Microsimulation. <i>JCO Oncology Practice</i> , 2021, 17, e1055-e1074.	1.4	3

#	ARTICLE	IF	CITATIONS
620	Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer. <i>Cancers</i> , 2021, 13, 4455.	1.7	73
621	Balanced dual acting compounds targeting aromatase and estrogen receptor $\hat{\pm}$ as an emerging therapeutic opportunity to counteract estrogen responsive breast cancer. <i>European Journal of Medicinal Chemistry</i> , 2021, 224, 113733.	2.6	11
622	Most women with breast cancer about to initiate aromatase inhibitors already have bone loss. <i>Medicina Clinica Practica</i> , 2021, 4, 100156.	0.2	0
623	Aromatase inhibitors and models for breast cancer. , 2006, , 23-44.		3
624	Adjuvant Hormonal Therapy for Early-Stage Breast Cancer. <i>Cancer Treatment and Research</i> , 2008, 141, 63-78.	0.2	1
625	Resistance to Antiestrogens. , 2006, , 413-433.		1
626	Ductal Carcinoma in Situ. , 2010, , 201-225.		2
627	Maligne Tumoren der Mamma. , 2019, , 1-31.		1
629	The Treatment of Breast Cancer. , 1974, , .		104
630	Primary Prevention of Breast Cancer. , 2009, , 349-369.		1
631	Metabolic Bone Disease. , 2011, , 1305-1349.		3
632	Data from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trial. <i>Clinical Cancer Research</i> , 2004, 10, 355s-361s.	3.2	25
633	Issues Patients would like to Discuss at their Review Consultation in Breast Cancer Clinics â€” a Cross-sectional Survey. <i>Tumori</i> , 2014, 100, 568-579.	0.6	12
634	Issues patients would like to discuss at their review consultation in breast cancer clinics—a cross-sectional survey. <i>Tumori</i> , 2014, 100, 568-79.	0.6	10
635	Exercise Recommendations for Cancer-Related Fatigue, Cognitive Impairment, Sleep Problems, Depression, Pain, Anxiety, and Physical Dysfunctionâ€”A Review. <i>Oncology & Hematology Review</i> , 2012, 08, 81.	0.2	118
636	Incidence of menopausal symptoms in postmenopausal breast cancer patients treated with aromatase inhibitors. <i>Oncotarget</i> , 2017, 8, 40558-40567.	0.8	28
637	Adjuvant Endocrine Therapy for Hormone-positive Breast Cancer, Focusing on Ovarian Suppression and Extended Treatment: An Update. , 2017, 37, 5329-5341.		18
638	Adjuvant Endocrine Therapy in Breast Cancer: A Novel e-Health Approach in Optimizing Treatment for Seniors (OPTIMUM): A Two-Group Controlled Comparison Pilot Study. <i>JMIR Research Protocols</i> , 2016, 5, e199.	0.5	7

#	ARTICLE	IF	CITATIONS
639	OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer. Health Technology Assessment, 2016, 20, 1-202.	1.3	53
640	Cancer Therapy Disparity: Unequal Access to Breast Cancer Therapeutics and Drug Funding in Canada. Current Oncology, 2007, 14, 3-10.	0.9	14
641	Matters of the Heart: Cardiac Toxicity of Adjuvant Systemic Therapy for Early-Stage Breast Cancer. Current Oncology, 2008, 15, 16-29.	0.9	19
642	Cancer Treatment-Related Bone Loss: A Review and Synthesis of the Literature. Current Oncology, 2008, 15, 30-40.	0.9	41
643	Cost-Effectiveness Analysis of Adjuvant Hormonal Treatments for Women with Postmenopausal Hormone-Receptor Positive Early Breast Cancer in the Korean Context. Journal of Breast Cancer, 2010, 13, 286.	0.8	5
644	Interventions to Alleviate Symptoms Related to Breast Cancer Treatments and Areas of Needed Research. Journal of Cancer Science & Therapy, 2011, 01, .	1.7	7
645	Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer. World Journal of Clinical Oncology, 2014, 5, 248.	0.9	48
646	Editorial: Tailoring treatment to patients with early breast cancer " can we deliver?. Women's Oncology Review, 2004, 4, 69-70.	0.0	0
647	A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. Women's Oncology Review, 2004, 4, 127-128.	0.0	0
648	Breast surgery in the "Arimidex, Tamoxifen alone or in combination" (ATAC) trial: American women are more likely than women from the United Kingdom to undergo mastectomy. Women's Oncology Review, 2004, 4, 305-306.	0.0	0
649	Mammakarzinom der Frau. , 2006, , 4215-4331.		2
650	Possible additional therapeutic uses of aromatase inhibitors. , 2006, , 157-175.		0
651	Recent Advances in Adjuvant Systemic Treatment for Breast Cancer: All Systems Go!. Current Oncology, 2006, 13, 147-159.	0.9	0
652	Recovery of Ovarian Function with Aromatase Inhibitors: In Young Breast Cancer Patients (<45) with Chemotherapy-induced Amenorrhea. Journal of Breast Cancer, 2008, 11, 133.	0.8	1
654	Endocrine Therapy for Breast Cancer. , 2008, , 411-434.		0
656	Endocrine Therapy with Selective Estrogen Receptor Modulators (SERMs) and Aromatase Inhibitors in the Prevention and Adjuvant Therapy Settings. Cancer Treatment and Research, 2009, 147, 1-29.	0.2	1
657	Strategies of Hormonal Prevention. Cancer Treatment and Research, 2009, 147, 1-35.	0.2	0
658	Targeted Approaches to Drug Development. , 2009, , 57-98.		3

#	ARTICLE	IF	CITATIONS
659	Hormonotherapy of Bone Metastases. Cancer Metastasis - Biology and Treatment, 2009, , 299-320.	0.1	0
661	Endocrine Therapy for Breast Cancer. , 2009, , 1263-1285.		0
662	Hormonal therapies in Breast and Prostate Cancer: Effects on Bone and the Role of Bisphosphonates. , 2010, , 205-218.		0
664	Chemoprevention of Breast Cancer. , 2010, , 569-583.		0
665	Hormone Receptor Positive Early Breast Cancer: What Role for Aromatase Inhibitors?. Clinical Medicine Reviews in Oncology, 0, 2, 89-98.	0.0	0
667	Adjuvant Therapy and Breast Reconstruction. , 2010, , 19-28.		1
668	Basic Principles of Antineoplastic Therapies. , 2010, , 707-715.		0
670	Maligne Tumoren der Mamma. , 2011, , 1-31.		2
671	Les cancers du sein Nâ”, HER2 nÃ©gatifs, RH+: Quelles hormonothÃ©rapies? Quand faut-il faire une chimiothÃ©rapie?. , 2012, , 457-470.		0
672	Controversies in Adjuvant Endocrine Therapy for Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 20-26.	1.8	1
673	Systemic hormonal therapies for early-stage breast cancer. , 2013, , 463-477.		0
674	Ductal carcinoma <i>in situ</i>: how should we treat it?. Breast Cancer Management, 2013, 2, 245-256.	0.2	0
675	Endocrinologic Issues. , 2015, , 343-360.		0
676	Bisphosphonates for Osteoporosis. , 2015, , 345-371.		2
677	Epidemiology, Risk Factors, and Prevention. , 2016, , 57-87.		1
678	The Long-Term Endocrine Sequelae of Multimodality Cancer Therapy. , 2016, , 1799-1832.		0
679	Onco-cardiology for Breast Cancer. , 2016, , 889-921.		0
681	InforMatrix Aromatase Inhibitors in Breastcancer. Journal of Pharmaceutical Care & Health Systems, 2016, 1, .	0.1	0

#	ARTICLE	IF	CITATIONS
682	Menopause Symptoms. , 2018, , 277-299.		1
683	Practical consensus recommendations on ovarian suppression in early breast cancer (adjuvant). South Asian Journal of Cancer, 2018, 07, 151-155.	0.2	1
684	Bone-Targeted Therapies in Adjuvant Setting. , 2019, , 27-39.		0
685	Breast Cancer in Older Women. , 2019, , 325-335.		1
686	Onco-Cardiology for Breast Cancer. , 2019, , 757-779.		0
687	Epidemiology, Risk Factors, and Prevention. , 2019, , 39-61.		1
688	The synthesis and the study of the antitumor activity of 3-R-6-(4-methoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine hydrobromides. Journal of Organic and Pharmaceutical Chemistry, 2020, 18, 28-35.	0.0	0
689	Maligne Tumoren der Mamma. , 2014, , 1-30.		0
690	Aromatase inhibitors and models for breast cancer. , 2008, , 23-44.		0
691	Clinical studies with exemestane. , 2008, , 53-68.		0
692	Clinical studies with anastrozole. , 2008, , 101-125.		0
693	The third-generation aromatase inhibitors: a clinical overview. , 2008, , 127-146.		0
694	Possible additional therapeutic uses of aromatase inhibitors. , 2008, , 165-183.		0
697	Maligne Tumoren der Mamma. , 2005, , 1-30.		0
702	Adjuvant endocrine therapy for postmenopausal women with early stage breast cancer. Therapy: Open Access in Clinical Medicine, 2004, 1, 305-318.	0.2	0
703	Prevention of Breast Cancer. , 2006, , 63-94.		0
704	Ductal Carcinoma In Situ: Systemic Treatment. , 2006, , 137-156.		0
707	Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer. MedGenMed: Medscape General Medicine, 2005, 7, 20.	0.2	6

#	ARTICLE	IF	CITATIONS
708	Bisphosphonate therapy for women with breast cancer and at high risk for osteoporosis. Journal of the National Medical Association, 2007, 99, 35-45.	0.6	3
709	Aromatase inhibitors and bone loss. Oncology, 2006, 20, 1029-39; discussion 1039-40, 1042, 1048.	0.4	30
710	Prevention, diagnosis and treatment of osteoporosis following menopause induced due to oncological disease. Clinical Cases in Mineral and Bone Metabolism, 2009, 6, 261-3.	1.0	1
711	Breast cancer (non-metastatic). Clinical Evidence, 2007, 2007, .	0.2	1
714	Breast cancer (non-metastatic). Clinical Evidence, 2011, 2011, .	0.2	1
715	Social network analysis of physician interactions: the effect of institutional boundaries on breast cancer care. AMIA ... Annual Symposium proceedings, 2011, 2011, 152-60.	0.2	11
716	Recent advances in adjuvant systemic treatment for breast cancer: all systems go!. Current Oncology, 2006, 13, 147-59.	0.9	0
718	An Uncommon Pairing of common Tumors: Case Report of Ductal Carcinoma Within Fibroadenoma. Hawai'i Journal of Medicine & Public Health: A Journal of Asia Pacific Medicine & Public Health, 2019, 78, 39-43.	0.4	1
719	Hormonal and Targeted Treatments in Breast Cancer. , 2022, , 443-463.		3
720	The efficacy of a comprehensive bone health program in maintaining bone mineral density in postmenopausal women with early-stage breast cancer treated with endocrine therapy: real-world data. Irish Journal of Medical Science, 2022, 191, 2511-2515.	0.8	2
721	Breast Cancer Risk Assessment and Management of the High-Risk Patient. Obstetrics and Gynecology Clinics of North America, 2022, 49, 87-116.	0.7	3
722	Estrogen Receptor Complex to Trigger or Delay Estrogen-Induced Apoptosis in Long-Term Estrogen Deprived Breast Cancer. Frontiers in Endocrinology, 2022, 13, 869562.	1.5	3
723	Evaluating the role of aromatase inhibitors in the treatment of low-grade endometrial stromal sarcomas. Gynecologic Oncology Reports, 2022, 40, 100980.	0.3	0
724	Artificial intelligence opportunities in cardio-oncology: Overview with spotlight on electrocardiography. American Heart Journal Plus, 2022, 15, 100129.	0.3	11
725	Impact of Endocrine Therapy Adherence on Outcomes in Elderly Women with Early-Stage Breast Cancer Undergoing Lumpectomy Without Radiotherapy. Annals of Surgical Oncology, 2022, 29, 4753-4760.	0.7	5
726	Adherence to hormone therapy in women with breast cancer: a quantitative study. Professioni Infermieristiche, 2016, 69, 113-21.	1.0	8
727	Hormonal Crosstalk Between Thyroid and Breast Cancer. Endocrinology, 2022, 163, .	1.4	11
728	Influence of the anti-estrogens tamoxifen and letrozole on thyroid function in women with early and advanced breast cancer: A systematic review. Cancer Medicine, 2023, 12, 967-982.	1.3	10

#	ARTICLE	IF	CITATIONS
729	Short-Term Changes in Ki-67 during Neoadjuvant Treatment of Primary Breast Cancer with Anastrozole or Tamoxifen Alone or Combined Correlate with Recurrence-Free Survival. <i>Clinical Cancer Research</i> , 2005, 11, 951s-958s.	3.2	269
730	Endocrine Therapy Trials of Aromatase Inhibitors for Breast Cancer in the Adjuvant and Prevention Settings. <i>Clinical Cancer Research</i> , 2005, 11, 900s-905s.	3.2	28
731	Clinical Outcomes of Adjuvant Hormone Therapy in a Cohort of Patients With Infiltrating Non-metastatic Breast Cancer in a Latin American Cancer Center. <i>Cureus</i> , 2022, , .	0.2	0
732	Evaluation of metabolic syndrome and obesity in breast cancer survivors undergoing interdisciplinary approach: a prospective cohort study. <i>Mastology</i> , 0, 32, .	0.1	0
733	Breast Cancer and the Cardiovascular Disease: A Narrative Review. <i>Cureus</i> , 2022, , .	0.2	7
734	Electro-Oxidation of Tamoxifen on Nanozeolite NaY Modified Carbon Paste Electrode. <i>Russian Journal of Electrochemistry</i> , 2022, 58, 689-703.	0.3	2
735	Exemestane for Breast Cancer Prevention: A Feasible Strategy?. <i>Clinical Cancer Research</i> , 2005, 11, 918s-924s.	3.2	6
736	A prospective analysis of two studies that used the 5-mm interval slices and 5-mm margin-free method for ipsilateral breast tumor recurrence after breast-conserving surgery without radiotherapy. <i>Breast Cancer</i> , 2023, 30, 131-138.	1.3	2
738	A patient with stage IIIB advanced breast cancer who is still alive 24 years after surgery: a case report and remarks on the treatment strategies. <i>Translational Cancer Research</i> , 2022, 11, 3903-3911.	0.4	1
739	Long-Term Outcome of Sustained Endocrine Monotherapy for Elderly Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2023, 30, 1671-1677.	0.7	1
741	Incidence and prognostic significance of receptor discordance between primary breast cancer and paired bone metastases. <i>International Journal of Cancer</i> , 2023, 152, 1476-1489.	2.3	3
742	Bone Turnover Markers: Basic Biology to Clinical Applications. <i>Endocrine Reviews</i> , 2023, 44, 417-473.	8.9	43
743	Cost-Effectiveness Analysis of Ultra-Hypofractionated Whole Breast Radiation Therapy Alone Versus Hormone Therapy Alone or Combined Treatment for Low-Risk ER-Positive Early Stage Breast Cancer in Women Aged 65 Years and Older. <i>International Journal of Radiation Oncology Biology Physics</i> , 2023, 116, 617-626.	0.4	1
744	Dehydroxylative Cyanation of Alcohols Promoted by Triphenylphosphine/1,2-Diiodoethane. <i>Synlett</i> , 0, , .	1.0	0
745	The Cardiovascular Risks Associated with Aromatase Inhibitors, Tamoxifen, and GnRH Agonists in Women with Breast Cancer. <i>Current Atherosclerosis Reports</i> , 2023, 25, 145-154.	2.0	2